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Chapter 1: Amyloidosis: definition and mechanisms 
 
The word amyloid, meaning cellulose-like, was firstly introduced by Virchow in 1851. The 
pathologist detected a positive iodine-staining reaction during the histopathological 
examination of some human livers, which actually appeared very similar to that displayed by 
the extracellular material of wood and starch. The positive iodine-staining in the deposits 
detected was likely due to the presence of sulphate proteoglycans, now recognized as a 
common constituent of amyloid deposits. The term amyloid was hence conserved, though a 
few years later it was demonstrated that amyloid had a protein nature (Friedreich and Kekule, 
1859). Amyloid is constituted by insoluble fibrils with a β- pleated sheet conformation, 
mostly deriving from the proteolysis of a normally soluble protein precursor (Sipe, 1994). 
Following cleavage of such precursor, the proteolytic fragments produced undergo 
pathological conformational changes into a β-sheet structure, which reduces their solubility, 
inducing their polymerization and subsequent aggregation. Fibrils are rigid, fine, non-
branching, 8-10 nm wide and indeterminate in length, with the β-sheet conformation 
presenting a green birefringence under polarized light when stained with Congo Red or green 
fluorescence when stained with thioflavin T (Forloni et al., 1996). Amyloidoses can therefore 
be considered pathologic conditions caused by protein conformation disorders, i.e. 
“misfolding” diseases.  The deposits of amyloid substance differ in protein composition 
depending upon the type of amyloidosis and the different clinical forms which may be 
encountered. This indicates that amyloid is a biochemically heterogeneous substance, 
although displaying similarities in properties and staining characteristics. At present 20-25 
different types of proteins with the ability to aggregate, insolubilize, and deposit in tissue as 
amyloid have been identified (Murphy et al., 2001; Gruys, 2004; Woldemeskel, 2012) (Table 
1).  
Although amyloidosis is heterogeneous with regard to the biochemical composition and 
anatomical distribution of amyloid fibrils there are some common factors at the basis of the 
process of amyloid formation. Firstly, as formerly introduced, the involvement of a precursor 
protein that encompasses an amyloidogenic motif. Precursor proteins may undergo 
conformational changes following prior proteolysis, as happens in most cases, or even 
avoiding such cleavage. Secondly, the elevation of serum/tissue levels of the amyloid 
precursor protein, reflecting its overproduction, or impaired clearance, or both. Thirdly, the 
abnormal processing of precursor proteins, which is probably the most complex and not yet 
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fully disclosed issue in amyloidogenesis, in which genetic predisposition and disfunctions of 
the immune system seem to be involved.  In some cases, the aberrant processing might be 
determined by mutant genetic variants of the precursor itself; in others, the precursors are 
normal wild type proteins, but impaired cellular functions or post-translational modifications 
may cause their incomplete degradation. Normally, misfolded proteins are degraded 
intracellularly in proteasomes or extracellularly by macrophages, which in amyloidosis fail to 
occur. The concept of processing also involves a group of amyloid associated proteins 
(chaperones) such as amyloid P component, glycosaminoglycans, apolipoprotein E and J 
(Castano et al., 1991). Further, the importance of tissue-related enzymes and their inhibitors 
may account for some of the regional selectivity of amyloid deposition, for example in vessel 
walls, brain parenchyma or peripheral nerves. Regarding humans, amyloidosis appears to be 
associated with a range of medical disorders including cancer, rheumatoid arthritis, chronic 
renal dialysis, familial amyloid polyneuropathy and diabetes. Thus, amyloid is supposed to be 
involved in ageing, lipid metabolism, acute phase response, peripheral nerve function, 
neuronal degeneration and infection with non-classical agents.  
The clinical presentation of amyloidosis is also quite variable depending on the protein types 
and tissues involved and on the extent of functional disruption of the affected organs in the 
different species.  
 
1.1 Amyloid nature and its distribution: the basis for the classification of 
amyloidosis 
 
According to the WHO-IUIS Nomenclature Subcommittee (WHO-IUIS, 1993) on the 
nomenclature of amyloid and amyloidosis, amyloidosis is classified based on the amyloid 
fibril protein, followed by a designation of the fibril protein precursor. Therefore the capital 
letter A for amyloid is followed by the protein designation in abbreviated form (Table 1).  
For example AL-amyloid refers to the amyloid derived from an immunoglobulin light chain 
or immunoglobulin heavy chain fragment (Gertz, 2004). In AL-amyloidosis unstable 
monoclonal immunoglobulin light chains, produced by a plasma cell discrasia, lead to the 
formation and deposition of fibrils. AL-amyloidosis is very rare in domestic animals, with 
few reports available describing systemic forms and few more cases reporting localized 
deposits. On the contrary, in humans the AL-amyloid type is the most common form of 
systemic amyloidosis. 
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The amyloid fibril protein in the immunoglobulin heavy chain has been given the designation 
AH.  
AA-amyloid refers to the amyloid derived from serum A-amyloid protein (SAA), a high 
density lipoprotein with apoSAA as its precursor protein. AA-amyloidosis, besides being 
characterized by an increased level of SAA, which is common in inflammatory states, might 
be due to defects in the degrading monocyte-derived enzymes or to a genetically determined 
structural abnormality in the SAA molecule. AA amyloidosis is the most common form of 
amyloidosis in domestic animals. It is associated with chronic inflammatory or neoplastic 
diseases, or it may even be idiopathic, where no underlying disease is found. In AA 
amyloidosis the deposition in most species is in the central organs and tissues such as spleen 
liver, kidney and the arterial walls. 
Some species of animals appear to have genetic predisposition to AA amyloidosis. Familial 
amyloidosis is reported in Siamese and Abyssinian cats (Boyce J.T. et al., 1984) and Shar Pei 
dogs (DiBartola S.P. et al., 1990) with AA-proteins differing in primary sequences and 
deposition patterns. The kidney is the main target organ for the deposition of amyloid in the 
Abyssinian cat and Shar Pei dogs, while the amyloid protein is mainly deposited in the liver 
in Siamese cats. 
To give further insights into the classification, islet amyloid polypeptide is a precursor for 
AIAPP amyloid protein deposited in pancreatic amyloidosis. The deposition of islet amyloid 
polypeptide, a normal protein secreted by the β cells of the pancreas, is reported in pancreas 
of cats and macaques.  
Eventually, another commonly recurring form of amyloidosis is due to the beta-amyloid (Aβ), 
which characterizes a variety of diseases such as Alzheimer’s disease (AD), Down Syndrome 
(DS) and Dutch forms of hereditary cerebral hemorrhage with amyloidosis.  
According to the extent of deposition in bodily tissues of man and animals, amyloidosis is 
classified as systemic or localized. Both the aforementioned types include inherited and non-
inherited forms. 
Amyloidosis involving several tissues and organs throughout the body is referred to as 
systemic amyloidosis, which can be due to AL-amyloidosis, AA-amyloidosis or familial 
forms of amyloidosis. Familial amyloidosis in humans could be due to mutations in 
fibrinogen, lysozyme, apolipoprotein AI, and transthyretin (with ATTR as amyloid protein). 
Conversely, amyloid substance may also be confined at a given area in the body in the form 
of localized amyloidosis. 
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Various forms of local amyloid deposits are known in animals and humans. They include 
deposition of Aβ protein in AD, AIAPP in pancreatic islets and AANF in atrial amyloid 
deposit.  
Regarding systemic amyloidosis, the affected organs may be enlarged and exhibit variable 
pallor grossly, or the amyloid deposit may be detected only after microscopic examination of 
the affected tissues without distinct grossly discernible lesions. In systemic amyloidosis 
amyloid appears as a pale eosinophilic homogenous extracellular deposit in tissues.  
In localized forms of amyloidosis the amyloid fibrillar protein is deposited at a given site in 
an organ or tissue either as a grossly visible mass or as a microscopic deposit. For instance, 
localized AL-amyloidosis is characterized by limited growth of monoclonal plasma cells and 
restriction of amyloid deposits to the adjacent sites to those of the synthesis of the precursor 
(Merlini and Stone, 2006).  
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Amyloid protein 
a,b 
 
Protein precursor Protein type Clinical diagnosis 
AA apoSAA  
Reactive (secondary) amyloidosis, 
familial mediterranean 
fever, familial amyloid nephropathy 
with urticarial and 
deafness (Muckie-Wells’ syndrome) 
 
AL κλ, for example, κIII 
 
Aκ, Aλ, for example, 
AκIII 
 
Idiopathic (primary) amyloidosis 
associated with 
myeloma/macroglobulinaemia 
AH IgG1 (γ1) Aγ1  
ATTR Transthyretin 
For example, Met 30c 
For example, Met III 
TTR or IIe 122 
Familial amyloid polyneuropathy, 
Portuguese 
Familial amyloid cardiomyopathy, 
Danish 
Systemic senile amyloidosis 
AApoAI apoAI Arg 26 
Familial amyloid polyneuropathy, 
Iowa 
AGel Gelsolin Asn 187d (15) Familial amyloidosis, Finish 
ACys Cystatin C Gin 68 
Hereditary cerebral hemorrhage with 
amyloidosis, Icelandic 
Aβ 
β protein precursor for 
example, βPP 695e 
Gin 618 (22) 
Alzheimer’s disease, Down 
syndrome, and hereditary 
cerebral hemorrhage with 
amyloidosis, Dutch 
Aβ 2M β2-microglobulin  Associated with chronic dialysis 
AScr 
Scrapie protein precursor Scrapie protein 27–30 
Creutzfeldt-Jakob disease, and so 
forth 
33–35f cellular form For example, Leu 102 
Gerstmann-Straüssler-Scheinker 
syndrome 
ACal (Pro)calcitonin (Pro)calcitonin 
In medullary carcinomas of the 
thyroid 
AANF Atrial natriuretic factor  Isolated atrial amyloid 
AIAPP 
Islet amyloid 
polypeptide 
 
In islets of Langerhans, 
 diabetes type II, insulinoma 
AInsg Insulin  Islet amyloid in the degu (a rodent) 
AApoAIIg apoAII (murine) Gin5 
Amyloidosis in senescence,  
accelerated mice 
  
   Table 1: Nomenclature and classification of amyloid and amyloidosis. Source: WHO/IUIS Nomenclature 
subcommittee. 
aNonfibrillar proteins, for example, protein AP (amyloid P-component) excluded. 
bAA: amyloid A protein; SAA: serum amyloid A protein; apo: apolipoprotein; L: immunoglobulin light chain; H: 
immunoglobulin heavy chain. 
cATTR Met 30 when used in text. 
dAmino acid position in the mature precursor protein. The position in the amyloid fibril protein is given in parentheses. 
eNumber of amino acid residues; fMolecular mass (kilodaltons); gNot found in humans. 
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1.2 Cerebral amyloidosis and related neurodegenerative disorders 
 
Within the framework of localized forms of amyloidosis several neurodegenerative disorders 
are encountered.  
In the human population Aβ-amyloid is involved in various neuropathological affections, the 
most common of which is AD. This disorder, which will be further described more in details, 
can present as a sporadic or familial form, with a presenile or senile esordium. Familial forms 
with a presenile esordium may be due to mutations in the gene encoding the precursor of Aβ 
protein, defined as amyloid precursor protein (APP), or in the genes encoding for presenilins, 
enzymes involved in the processing of APP. Furthermore, a risk factor for the senile esordium 
of the disease is represented by the presence of at least one allele encoding for the ε4 isoform 
of apolipoprotein E. 
In AD deposition of Aβ fibrils occurs mainly extracellularly in the form of plaques but also 
intracellularly within neurons (LaFerla et al., 2007), and, in variable proportions, inside the 
blood vessels of the cerebral cortex and leptomeninges, where it gives origin to a 
neuropathological trait designated as congophilic angiopathy. 
Neuropathological features similar to those aforementioned characterize nearly all the patients 
affected by DS reaching the adulthood. This finding is likely to be ascribed to an increase of 
Aβ protein amount in Down patients, due to hyperdosage of the gene encoding for APP, given 
the presence of a supernumerary chromosome 21. 
Massive deposition of Aβ in the vessels of the cerebral cortex and leptomeninges, and, to a 
lesser extent, of cerebellum, basal ganglia and brainstem is the morphological substrate of a 
disease known as “Hereditary cerebral hemorrhage with amyloidosis, Dutch type”, which is a 
dominant autosomal disease due to a point mutation responsible for the substitution of the 
amino acid at position 22 of Aβ. The disease, identified in several Dutch families, is 
characterized by recurrent and often lethal phenomena of ictus, caused by hemorrhages and 
strokes, occurring between 45 and 60 years of age. 
In Iceland a familial form of cerebral amyloidosis due to the deposition of cystatin C in the 
small arteries has been identified. This severe congophilic angiopathy causes often lethal 
cerebral hemorrhages usually appearing between 20 and 40 years of age. The disease 
transmits by an autosomal dominant mechanism and is caused by a mutation at codon 68 of 
the gene encoding for cystatin C, determining a substitution of the amino acid leucine with 
glutamine. Unlike cerebral vascular amyloidosis due to deposition of Aβ, in the “Hereditary 
cerebral hemorrhage with amyloidosis, Icelandic” the amyloid deposition is systemic, 
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involving also blood vessel of extra cerebral tissues, such as salivary glands, spleen, testicles 
and skin. 
Amyloid deposits in the central nervous system have been described in patients affected by 
familial amyloid polyneuropathy, a disorder due to mutations in the gene encoding for 
transthyretin. This disease is characterized by lacking of clinical neurological symptoms, 
though amyloid deposits of transthyretin occur inside leptomeninges and leptomeningeal 
vessels, in the subependymal cerebral tissue and inside choroid plexi, and eventually in the 
superficial layers of brain and spinal cord. 
Another various group of neurological disorders categorized as cerebral amyloidosis is 
represented by prion diseases. Prion diseases are degenerative encephalopathies caused by 
protein misfolding disorders in which misfolding of the host-encoded prion protein (PrP) 
occurs. PrP may exist as a normal cellular prion protein, defined as PrP
C
 , and a pathogenic 
misfolded conformer, designated as PrP
Sc
. Unlike PrP
C
, PrP
Sc 
is insoluble and forms 
extracellular aggregates which can be amorphous or be structured as amyloid fibrils.  
PrP
Sc
 are infectious, naturally transmissible misfolded proteins with neurotoxic properties and 
cause fatal neurological diseases in humans and a wide range of animal species (Savistchenko 
et al., 2011). Sixteen different variants of prion disease have been identified in humans and 
animals (Imran and Mahmood, 2011). Animal prion diseases include scrapie of sheep and 
goats, bovine spongiform encephalopathy (BSE), transmissible mink encephalopathy (TME), 
chronic wasting disease of cervids (CWD) and feline spongiform encephalopathy of felids 
(FSE). 
In humans, prion diseases are traditionally classified into Creutzfeldt-Jacob disease (CJD), its 
variant form (vCJD) resulting from human infection by BSE prions, Gerstmann-Sträussler-
Scheinker disease (GSS) and fatal familial insomnia (FFI) (Savistchenko et al., 2011).  
Prion diseases can arise without any apparent cause as in sporadic Creutzfeldt-Jacob disease 
(sCJD) or due to genetic disorders linked to mutations in the endogenous PrP protein. The 
diseases can also be acquired by infection, through ingestion of contaminated products or 
through iatrogenic procedures and are in most cases experimentally transmissible (Imran and 
Mahmood, 2011). Infectivity and transmissibility of prion diseases has been much of a 
concern particularly since the outbreak of BSE in cattle. Cattle are infected with BSE when 
they ingest prion-contaminated meat and bone meal of ruminant origin contaminated with 
prions. Consumption of BSE-contaminated bovine tissues is associated with a fatal variant 
form of Creutzfeldt-Jacob disease (vCJD) in humans (Hill et al., 1997). 
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Amorphous deposits are the most common neuropathological feature of sCJD, which is 
mainly characterized by spongiosis of the cerebral and cerebellar cortices and of some 
subcortical nuclei. Only 10% of the patients affected by sCJD display deposits of PrP
Sc
-
amyloid, while the structured form of PrP
Sc
 fibrils as amyloid plaques is a neuropathological 
hallmark of vCJD, caused by transmission of the agent of BSE to man.  
In sCJD affected patients PrP
Sc
 amyloid plaques are mainly confined to the cerebellar cortex; 
in vCJD patients, instead, PrP
Sc
 plaques are detected both in the cerebral and cerebellar 
cortices and in the adjacent neuropil they present a peculiar surrounding rim of spongiosis, on 
the basis of which the term “florid plaque” has been coined. 
Cerebral PrP
Sc
- amyloid plaques have been detected in 80% of the patients affected by Kuru, 
a prion disease nearly disappeared, which has been described in some tribes of New Guinea 
devoted to ritual cannibalism. 
Eventually, PrP
Sc–amyloid is the neuropathological hallmark of another neurological disorder 
of man, the Gerstmann-Straüssler-Scheinker syndrome (GSS). It is an autosomic dominant 
familial disease which can be due to mutations at codons 102, 105, 117, 198, 212 and 217 of 
the PrP encoding gene (PRNP). In GSS PrP
Sc
 –amyloid accumulates in form of unicentric or 
multicentric deposits in the neuropil of cerebellum, cerebral cortex and in subcortical nuclei. 
It can be associated to spongiosis (as in case of mutation occurring at codon 102), or to 
alterations of the neuronal cytoskeleton (e.g. in case codon 198 and 217 are mutated). 
In a rare GSS variant due to mutation at codon 145 of PRNP amyloid is mainly deposited in 
the vessels of cerebral and cerebellar cortices, thus displaying in the form of “PrPSc vascular 
cerebral amyloidosis”. 
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Chapter 2: Aβ-amyloid in the brain: pathway of formation 
 
2.1 Basic knowledge of the amyloid precursor protein (APP) 
 
It was in the mid-1980s when brain amyloid plaques associated with AD were first purified 
and were found to consist of multimeric aggregates of Aβ polypeptide containing about 40 
amino acid residues (Glenner and Wong, 1984). Subsequent cloning of the complementary 
DNA (cDNA) of Aβ revealed that Aβ is derived from a larger precursor protein (Tanzi et al., 
1987). The full length DNA of the amyloid precursor protein (APP) was later isolated and 
sequenced and APP was predicted to be a glycosylated integral membrane cell surface 
receptor protein with 695 amino acids (Kang et al., 1987). The APP gene is located on 
chromosome 21 and contains 18 exons. Although alternative splicing of transcripts from the 
single APP gene results in several isoforms of the gene product, APP695, whose encoding 
cDNA lacks the gene sequence from exons 7 and 8, is preferentially expressed in neurons 
(Sandbrink et al., 1994). Two homologues of APP were also identified and named APP-like 
protein 1 and 2 (APLP1 and APLP2) (Coulson et al., 2000). APLP2, similarly to APP, is 
expressed ubiquitously while APLP1 is only expressed in the brain and is only found in 
mammals.  
The APP protein is a type I integral membrane protein with a large extracellular portion, a 
hydrophobic transmembrane domain, and a short C-terminus designated the APP intracellular 
domain (AICD) (Fig. 2a). The extracellular portion of APP contains two domains, E1 and E2. 
The precise physiological function of APP is not known and remains one of the vexing issues 
in the field.  
Because of its highly similar structure to the developmental signaling molecule Notch, APP 
has been proposed to function as a cell surface receptor (Zheng and Koo, 2011). Several 
studies have reported that certain ligands, including F-spondin, Nogo-66, netrin-1 and BRI2, 
bind to the extracellular domain of APP, resulting in modulated APP processing and 
sequential downstream signals (Matsuda et al. 2009; Zheng and Koo 2011). However, the 
physiological functions of these interactions remain to be determined. Nevertheless, APP is 
more widely accepted as a protein contributing to cell adhesion via its extracellular domain. 
Studies have demonstrated that the E1 and E2 regions of APP can interact with extracellular 
matrix proteins (Small et al. 1999). Furthermore, the E1 and E2 regions of APP were found to 
interact with themselves, in parallel or anti-parallel, forming homo- (with APP) or hetero-
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dimers (with APLPs) (Dahms et al., 2010). Recent studies also suggest APP/APLPs as 
synaptic adhesion molecules as silencing of APP led to defects in neuronal migration (Wang 
et al. 2009). 
In most studies, APP overexpression shows a positive effect on cell health and growth. This 
effect is epitomized in transgenic mice that overexpress wild-type APP and have enlarged 
neurons (Oh et al. 2009). In transiently transfected cell lines, APP modulates cell growth, 
motility, neurite outgrowth, and cell survival. In adult animals, intracerebral injections of the 
APP ectodomain can improve cognitive function and synaptic density (Meziane et al., 1998). 
 
2.2 APP processing 
 
APP is produced in large quantities in neurons and it is metabolized very rapidly (Lee et al., 
2008). After sorting in the endoplasmatic reticulum (ER) and Golgi, APP is delivered to the 
axon, where it is transported by fast axonal transport to synaptic terminals (Koo et al., 1990).  
Crucial steps in APP processing occur at the cell surface and in the Trans-Golgi network 
(TGN) (Fig. 1). From the TGN, some of the newly synthesized APP can be transported down 
the axon to the cell surface, where it takes insertion. There one of the two ascertained post – 
translational APP processings, the so called “non-amyloidogenic pathway”, may occur. 
According to this pathway APP is sequentially cleaved by α-secretase and γ-secretase (Fig. 
2b). Although most APP must pass through the cell surface as part of its processing, this step 
is very rapid, as a small amount of APP is on the surface at any point in time. The cleavage by 
α-secretase releases the sAPP-α fragment, which diffuses away extracellularly, and a 
membrane-associated C-terminal fragment consisting of 83 amino acids (APP C83). APP C83 
is further clived by γ-secretase to release P3 peptide and the AICD, both of which are 
degraded rapidly.  
Cleavage of APP by α-secretase is attributed to the ADAM (a disintegrin and 
metalloproteinase) family of proteases (Asai et al., 2003; Jorissen et al., 2010) and takes 
place, to a large extent, on the cell surface. However, there is some α-secretase activity in the 
TGN.  
The constitutively secreted sAPP-α has been found to be neuro-protective (Han et al. 2005; 
Ma et al., 2009). sAPP-α is thought to promote neurite outgrowth and synaptogenesis as well 
as cell adhesion (Mattson, 1997; Gakhar Koppole et al., 2008). Studies have found that sAPP-
α is a growth factor (Herzog et al., 2004) that regulates the proliferation of embryonic and 
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adult neural stem cells (Ohsawa et al.,1999; Caille et al., 2004). sAPP-α alone is able to 
rescue most of the abnormalities of APP deficient mice (Ring et al., 2007), implying that most 
of the physiological functions of APP are conducted by its extracellular domain. 
No biologically relevant roles are currently established for the carboxyterminal fragments 
APP C83 and P3 generated by α- and γ-secretase, respectively. Regarding AICD, as the 
molecule is quickly degraded after γ-cleavage, the biochemical features and physiological 
functions of AICD in vivo are difficult to study. 
Some of the APP directly sorted from the Golgi apparatus, as well as some of the APP present 
on the cell surface, can be further transported into clathrin-coated pits to endosomal 
compartments, containing the enzymes β-secretase and γ-secretase. There the “amyloidogenic 
pathway” of APP processing occurs. Firstly, β-cleavage at the ectodomain of APP generates 
an sAPP-β domain and the membrane associated APP C-terminal fragment C99 (APP C99). 
Subsequently, APP C99 is cleaved by γ-secretase to release Aβ which has neurotoxic 
properties (Fig. 2c). β-site APP cleaving enzyme 1 (BACE1) is the major β-secretase in the 
brain (Vassar et al., 1999). BACE 1 can also cleave APP at a more carboxy-terminal position, 
resulting in CTF89 (and Aβ 11-40 after γ-secretase cleavage). A related protein, BACE2, also 
can exert β-secretase activity (Hussain et al., 2000), but it is expressed at very low levels in 
the brain and is mostly confined to glial cells (Laird et al., 2005). BACE 1 was first identified 
and characterized in 1999 (Sinha et al., 1999), as a type 1 transmembrane aspartyl protease 
with its active site on the luminal side of the membrane. The originally identified full-length 
BACE1 has 501 amino-acids (BACE1-501) and is predominantly expressed in the perinuclear 
post-Golgi membranes, vescicular structures throughout the cytoplasm (Huse et al., 2002), as 
well as on the cell surface (Ehehalt et al., 2002). Although BACE1 reaches the plasma 
membrane due to vescicle traffic, it is recycled quickly, and very little BACE1-mediated APP 
cleavage occurs at the plasma membrane; instead APP is cleaved by BACE primarily in 
endocytic vescicles. 
The proteolytic fragment sAPP-β generated by β-secretase reportedly lacks most of the 
neuroprotective effects of sAPP-α (Furukawa et al., 1996). A recent study suggested that 
sAPP-β can be cleaved to generate an N-terminal fragment that is a ligand for death receptor 
6, activating caspase 6 which further stimulates axonal pruning and neuronal cell death 
(Nikolaev et al., 2009). Regarding the carboxy-terminal fragments CTF99 and CTF89 a 
biological role still has to be disclosed.  
The APP CTFs generated by both α-cleavage and β-cleavage are further processed by γ-
secretase. Distinct from α-/β-secretases, γ-activity involves a large proteinase complex 
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consisting of at least four major components (Presenilin1 or Presenilin2, Presenilin enhancer 
2 (PEN2), Anterior pharynx-defective 1 (APH1) and Nicastrin) (Vetrivel et al., 2006). 
Presenilins (PSs) were identified and cloned in the mid-1990s (Levy-Lahad et al., 1995). PSs 
are multi-transmembrane proteins and can be cleaved at the cytoplasmic loop between the 
six
th
 and seven
th
 transmembrane regions to generate an N-terminal and a C-terminal fragment 
during post-translational maturation (Thinakaran et al., 1996). The two fragments interact 
with each other and they are both necessary for γ-secretase activity.  
Nicastrin, identified as a protein that interacts with PS in 2000, is a type I membrane 
glycoprotein with a large ectodomain (Fagan et al., 2001). Nicastrin undergoes a 
glycosylation/maturation process that causes a conformation change in its ectodomain, which 
is crucial for the assembly and maturation of the γ-secretase complex and γ-activity (Chavez-
Gutierrez et al. 2008). Mature nicastrin can bind to the ectodomain of APP C-terminal 
fragments derived through α-/β-secretase cleavage and may act as a substrate receptor of γ-
secretase (Shah et al., 2005). 
PEN2 and APH1 are another two γ-secretase complex components that were originally 
identified as the enhancers of PSs (Francis et al., 2002). APH1 is a multiple transmembrane 
protein with seven transmembrane domains and a cytosolic C-terminus (Fortna et al., 2004). 
APH1 interacts with immature nicastrin and PS to form a relatively stable pre-complex which 
is then translocated to the trans-Golgi from the ER/cis-Golgi for further maturation (Niimura 
et al., 2005). PEN2 is a hairpin-like protein with two transmembrane domains and with both 
ends in the lumen (Crystal et al., 2003). PEN2 is found to mediate the endoproteolysis of PS 
(Luo et al., 2003). 
The γ-secretase complex is assembled in sequential steps. Nicastrin and APH1 initially form a 
subcomplex and then PS binds to the Nicastrin-APH1 subcomplex. The joining of PEN2 
results in a conformation-dependent activation of γ-secretase (Niimura et al., 2005). Nicastrin, 
PEN2, APH1 and PS interact with each other and also mutually modulate each other (Kaether 
et al., 2004). 
γ-Secretase cleaves APP at multiple sites and in sequential steps to generate Aβ peptides of 
different lengths. 
The majority of Aβ peptides produced are 40 amino acids long (Aβ 40), however, peptides 
ranging from 38 to 43 amino acids are found in vivo. A small proportion (approximately 
10%) of Aβ forms is the 42 residue variant (Aβ42). Some Aβ forms (e.g. Aβ 1-42, Aβ 3-40) 
are considered more hydrophobic and more prone to fibril formation than others (e.g. Aβ 1-40 
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or 1-38) (Jarrett et al., 1993). Aβ42, the more amyloidogenic species, is also the predominant 
isoform found in cerebral plaques (Perl D. P., 2010).  
Besides the dominant γ-cleavage site at 40 and 42 residues, ζ-cleavage at 46 and ε-cleavage at 
49 residues are also thought to be mediated by γ-secretase (Weidemann et al., 2002; Zhao et 
al., 2004). Accordingly, various AICDs (C50, C53, C57 and C59) can be generated during 
these multi-site cleavages by γ-secretase. Interestingly, as the substrate of γ-secretase, APP 
itself can regulate the intracellular trafficking and cell surface delivery of PS1 (Liu et al., 
2009). In addition, APP has been found to possess a domain that negatively modulates γ-
secretase activity in Aβ production by binding to an allosteric site within the γ-secretase 
complex (Zhang and Xu 2010). These results reveal a novel mutual regulation between γ-
secretase and its substrate. 
 
2.3 Aβ accumulation process 
 
2.3.1 Intraneuronal Aβ accumulation process 
Not long after the discovery of Aβ peptide as a component of extracellular amyloid plaques in 
the mid-1980s, descriptions of the presence of Aβ inside neurons began to appear in the 
literature. In the first study reporting the presence of intraneuronal Aβ, Aβ immunoreactive 
material was observed in neurons in the cerebellum, cerebrum and spinal cord of individuals 
either affected or not by AD. As the age of the partecipants in the study ranged from 38 to 83 
years, these findings suggested that the occurrence of intracellular Aβ might not be an age-
dependent event (Grunke-Iqbal et al., 1989). Since the original report, there have been a large 
number of studies on post-mortem AD, DS and transgenic mouse brains which have provided 
evidence for the presence of intracellular Aβ within neurons. Careful studies using C-terminal 
specific antibodies against Aβ40 and Aβ42 have established that most of the intraneuronal Aβ 
ends at residue 42, and not at residue 40 (Gouras et al., 2000). Furthermore, immunogold 
electron microscopy has been carried out to demonstrate that Aβ42 is localized to the outer 
membrane of multivescicular bodies (MVBs) of neurons in the human brain, where it is 
associated with synaptic pathology (Takahashi et al., 2002). MVBs are considered late 
endosomes and are formed from the early endosome system. 
Recent studies suggest that the buildup of intracellular Aβ may be an early event in the 
pathogenesis of AD and DS. In patients with mild cognitive impairment (MCI), intraneuronal 
Aβ immunoreactivity has been reported in brain regions that are more prone to the 
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development of early AD pathology, such as the hippocampus and the entorhinal cortex 
(Gouras et al., 2000). Similarly, it has been shown that the accumulation of intracellular Aβ 
precedes extracellular plaque formation in patients with DS (Gyure et al., 2001). These results 
suggest that the accumulation of intraneuronal Aβ is an early event in the progression of AD, 
preceding the formation of extracellular Aβ deposits. Indeed, it has been demonstrated that 
intraneuronal Aβ levels decrease as extracellular plaques accumulate (Mori et al., 2002). 
These conclusions are also consistent with results from transgenic mouse models, in which 
intracellular Aβ accumulation appears as an early event in the progression of the 
neuropathological phenotype, preceding the accumulation of extracellular Aβ plaques (Wirths 
et al., 2001). According to further studies on patients with AD and DS and controls it would 
seem that intraneuronal Aβ immunoreactivity appears in the first year of life, increases in 
childhood and stabilizes in the second decade of life, remaining high through adulthood even 
in healthy brains.  
Although intracellular Aβ accumulation is now ascertained, how intracellular Aβ builds up is 
still being addressed. To investigate this issue, it is pivotal to focus on APP cleavage and 
releasing from its parent protein, APP. As mentioned before, APP localizes to the plasma 
membrane, but also to the TGN, ER and endosomal, lysosomal (Kinoshita et al., 2003) and 
mitochondrial membranes (Mizuguchi et al., 1992). As Aβ generation may potentially occur 
wherever APP and β- and γ- secretase are localized, it is likely that this occurs in several 
cellular compartments. In case Aβ cleavage occurs inside the cell, then Aβ would be 
intracellular; if liberation of Aβ occurs at the plasma membrane or in the secretory pathway, 
then it would be released into the extracellular fluid. Both the pathways are likely to occur, 
but the majority of Aβ is secreted out of the cell, suggesting that Aβ is predominantly 
produced as part of the secretory pathway, or, to a lesser extent, at the plasma membrane. 
Actually APP which is not cleaved at the plasma membrane could be re-internalized into the 
early/late endosome system by endocytosis (Golde et al., 1992). The endosomes are a likely 
site of intraneuronal Aβ generation owing to their acidic nature – BACE1 has optimal activity 
at acidic pH, and APP and BACE1 interactions have been observed by fluorescence 
resonance energy transfer (FRET) microscopy within the endosomes (Kinoshita et al., 2003). 
BACE1 cleavage of APP inside endosomes results in the 99 amino-acid fragment C99, which 
can be re-directed to different compartments. It can be shuttled back to the ER to be processed 
into Aβ by ER γ-secretase, shuttled back to the plasma membrane where the γ-secretase 
complex is also found, or processed to Aβ within the endosome/lysosome system. Therefore 
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the internalization of APP by endocytosis is one of the important pathway for the generation 
of Aβ. 
Furthermore, besides the endosome system, strong evidence suggests that Aβ is also 
generated intracellularly along the secretory pathway (Busciglio et al., 1993). Actually it has 
been ascertained that Aβ42 and Aβ40 are produced in the ER (Wild-Bode et al., 1997) and in 
the TGN (Hartmann et al., 1997) respectively. Interestingly, these sites of Aβ  production were 
limited to neurons, as in non-neuronal cells both Aβ42 and Aβ40 were produced at the cell 
surface rather than intracellularly. 
In addition to Aβ being produced intracellularly, it is also possible that previously secreted 
Aβ, which forms the extracellular Aβ pool, may be taken up by cells and internalized into 
intracellular pools. Aβ can bind to various biomolecules of the plasma membrane, including 
lipids, proteins and proteoglycans. Consequently, it is likely that some intracellular Aβ is 
derived from extracellular Aβ pools, taken up into the cells through receptors or transporters. 
A number of putative Aβ transporters have been identified. 
Aβ binds to the α7 nicotinic acetylcholine receptor (α7nAChR) with high affinity, and it has 
been shown that this binding results in receptor internalization and accumulation of Aβ 
intracellularly (Nagele et al., 2002).  
Recent studies have also shown that apolipoprotein E (APOE) receptors, members of the low-
density lipoprotein receptor (LDLR) family, modulate Aβ production and Aβ cellular uptake 
(Bu et al., 2006). Another member of this family, the LDL receptor related protein (LRP), 
binds to Aβ directly, or through ligands such as APOE, and undergoes rapid endocytosis, 
facilitating Aβ cellular uptake (Bu et al., 2006). 
APOE*ε4 is the major genetic risk factor for AD, and it is notable that one of its functions 
appears to be to directly mediate the accumulation of intracellular Aβ. 
In addition to LRP and nicotinic receptors, Aβ internalization has been reported through the 
scavenger receptor for advanced glycation end products (RAGE), in neurons and microglia 
(Deane et al., 2003). In addition to these downstream effects, it has been demonstrated that 
RAGE–Aβ complexes are internalized and that they co-localize with the lysosomal pathway 
in astrocytes in the brain of patients with AD (Sasaki et al., 2001). 
The formyl peptide receptor-like 1 (FPRL1) is a G-protein-coupled receptor associated with 
inflammatory cells, including astrocytes and microglia, that binds to Aβ and mediates the 
chemotactic response to Aβ42. Internalization of Aβ is rapid and results in cytoplasmic Aβ 
aggregates that stain with Congo red in macrophages (Yazawa et al., 2001). 
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Neuronal Aβ uptake has also been shown to be mediated through NMDA (Nmethyl-d-
aspartate) receptors. Blocking this NMDA receptor–Aβ internalization prevents 
pathogenicity, including increased microglial activation and cathepsin D levels (Bi et al., 
2002). 
It is plausible that intracellular Aβ has different roles in different cell types and that 
internalization in glial cells may be part of the regulatory system that seeks to control rising 
extracellular Aβ levels by taking the peptides up and degrading them. In neurons, the effects 
of intracellular Aβ are likely to be different.  
 
2.3.2 Pathological role of intracellular Aβ in vivo 
A recent study characterizing intracellular accumulation of Aβ in humans, including patients 
with AD, concluded that intracellular Aβ was abundantly present, and apparently 
independently of plaque load or formation of neurofibrillary tangles (NFT) (Wegiel et al., 
2007). The investigation of the functional consequences of intracellular Aβ in the human 
brain is limited to correlational studies in post-mortem brains. To better address the 
consequences of intracellular Aβ, animal models provide significant advantages that extend 
beyond mere correlations. 
Within neurons, Aβ42 appears to be predominantly localized to MVBs and lysosomes (Fig. 
3). In mouse experimental models (Langui et al., 2004) Aβ-containing MVBs were most often 
located in the perinuclear region.  
It has recently been shown that Aβ accumulation within MVBs is pathological, leading to 
disrupted MVB sorting via inhibition of the ubiquitin–proteasome system (Almeida et al., 
2006). As the proteasome is primarily located within the cytosol, and as Aβ has been shown 
to inhibit the proteasome directly (Gregori et al., 1995), this observation suggests that 
intracellular Aβ within the MVBs is mechanistically linked to cytosolic proteasome 
inhibition. The proteasome inhibition has been demonstrated to lead to higher Aβ levels, both 
in vivo and in vitro (Oddo et al., 2006a; Tseng et al., 2005), suggesting that the proteasome 
degrades Aβ, and that Aβ must be within the cytosolic compartment for this degradation to 
occur. MVBs are also viewed as major transport organelles within neuronal processes (Weible 
and Hendry, 2004), and Aβ accumulation in their outer membranes may disrupt vital cargo 
transport. Endosomal vescicles such as MVBs are an ideal location for Aβ aggregation, since 
the lipid membranes and low pH within these vescicles favor Aβ aggregation. Actually Aβ 
20 
 
oligomerization was observed within endosomal vescicles with AD pathogenesis using 
oligomer specific antibodies (Takahashi et al., 2004). 
In Tg2576 mice, accumulation of Aβ has also been observed in mitochondria (Manczak et al., 
2006), organelles in which all subunits of the γ-secretase have been located. Progressive 
accumulation of intracellular Aβ in mitochondria is associated with diminished enzymatic 
activity of respiratory chain complexes III and IV, and a reduced rate of oxygen consumption 
(Caspersen et al., 2005). These observations may help to explain the multitude of 
mitochondrial defects described in AD and mouse models of the disease (Keil et al., 2006). 
There is evidence for a role for intraneuronal Aβ in synaptic dysfunction, which could 
underlie cognitive deficits. The 3xTg-AD mouse model of AD develops intraneuronal 
accumulation of Aβ at 4 months of age, which is when cognitive deficits are first detected 
(Billings et al., 2005). Furthermore, the electrophysiological responses were recorded, and it 
was found that the appearance of intraneuronal Aβ led to a profound deficit in long-term 
potentiation (LTP) (Oddo et al., 2003), a form of synaptic transmission thought to underlie 
memory.  
Aβ is produced as a monomer, but readily aggregates to form multimeric complexes. These 
complexes range from low molecular weight dimers and trimers to higher molecular weight 
protofibrils and fibrils. The oligomeric species of Aβ have been found to be the most 
pathological, from dimers disrupting learning and memory, synaptic function and long term 
potentiation (LTP) (Cleary et al., 2005; Walsh et al., 2002), to dodecamers affecting cognition 
and memory in transgenic mouse models (Lesne et al., 2006). It has been shown that in tissue 
derived from human brain, Aβ oligomerization initiates within cells rather than in the 
extracellular space (Walsh et al., 2000).  
Aβ oligomerization has also been shown to occur during interactions with lipid bilayers, in 
particular cholesterol- and glycosphingolipid-rich microdomains known as lipid rafts (Kim et 
al., 2006) : it was found that Aβ fibrillogenesis was accelerated in the presence of plasma and 
endosomal and lysosomal membranes (Waschuk et al., 2001). 
 
2.3.3 Accumulation process and role of extracellular Aβ 
The intraneuronal Aβ deposition process does not counter the established evidence for a 
pathogenic role also for Aβ secreted extracellularly as part of the constitutive secretory 
pathway (Walsh and Selkoe, 2004). Furthermore, Aβ accumulating and aggregating in 
dystrophic and degenerating neuronal processes and synapses eventually leads to their 
dissolution and the subsequent extracellular localization of Aβ. 
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Aβ is thought to gradually increase in the extracellular space until it begins aggregating to 
form insoluble β-pleated amyloid plaques, which in turn may propagate Aβ toxicity to 
surrounding neurons and their processes. The fact that extracellular Aβ can influence 
intracellular Aβ suggests that Aβ may have prion-like properties.  
It remains to be established whether plaque formation depends on extracellular- or previously 
released intracellular- Aβ propagation to surrounding neuronal processes by a mechanism of 
permissive templating (self-seeding), or on the damage inflicted to Aβ surrounding neuronal 
processes secondary to the occurrence of inflammatory mechanisms. Inflammation, including 
the recruitment and activation of microglia, could lead to digestion of most of the degenerated 
neuronal remnants, while leaving indigestible Aβ behind as plaques. 
Extracellular Aβ oligomers have been shown to impair physiological processes involved in 
learning and memory, and injection of Aβ oligomers in rodent brains induced learning 
impairment (Cleary et al., 2005). 
The currently predominant hypothesis states that Aβ forms soluble oligomers in the 
extracellular space and that these oligomers inhibit NMDA-mediated synaptic transmission 
and ultimately cause spine and synapse loss through mechanisms not yet fully understood 
(Selkoe, 2000). 
 
2.3.4 Potential normal function of Aβ 
The constitutive generation and normal presence of Aβ in the brain supports the hypothesis 
that Aβ may have a normal physiological function, rather than merely being a toxic by-
product of APP processing. Neuronal excitation increases secretion of Aβ, which, in turn, 
depresses synaptic function decreasing neuronal activity. In this context, the Aβ peptide could 
have a negative feedback function preventing excitotoxicity (Kamenetz et al., 2003). 
Although excessive Aβ causes neurotoxicity, some studies have shown that Aβ 40 protects 
neurons against Aβ 42- induced neuronal damage and is required for the viability of central 
neurons (Plant et al., 2003; Zou et al., 2003). Moreover, two groups recently reported that low 
doses (picomolar) of Aβ  can positively modulate synaptic plasticity and memory by 
increasing hippocampal LTP (Morley et al., 2008; Puzzo et al., 2008), revealing a novel 
positive physiological function of Aβ under normal conditions. Picomolar levels of Aβ can 
also rescue neuronal cell death induced by inhibition of Aβ generation (by exposure to 
inhibitors of β - or γ-scretases) (Plant et al., 2003), possibly through regulating the potassium 
ion channel expression, hence affecting neuronal excitability (Plant et al., 2006). 
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Interestingly, according to other studies, Aβ has been shown to possess a number of trophic 
properties that emanate from the protein’s ability to bind Cu, Fe and Zn (Atwood et al., 2003). 
Actually Aβ belongs to a group of proteins that capture redox metal ions, thereby preventing 
them from participating in redox cycling with other ligands. The coordination of Cu appears 
to be crucial for Aβ’s own antioxidant activity that has been demonstrated both in vitro as 
well as in the brain, cerebrospinal fluid and plasma. Given that oxidative stress is one of the 
earliest pathological events in AD pathogenesis (Smith et al., 2000), as well as an increasing 
phenomenon during normal brain aging, in both cases promoting Aβ generation, the 
formation of Aβ diffuse amyloid plaques in the brain is likely to be seen as a compensatory 
response to remove reactive oxygen species. Within this perspective it has been proposed that 
Aβ deposition may act as a “sink” for trapping potentially harmful transition metal ions 
(particularly redox active metal ions) that can be released from metal-binding proteins by 
oxidative and mildly acidotic conditions, such as those accompanying acute brain trauma and 
AD, and that would otherwise catalyze adverse oxidation of biomolecules (Atwood et al., 
1998; Kontush et al., 2001). Therefore Aβ generation would be aimed at reducing oxidative 
damage, thereby preventing ROS-mediated neuronal apoptosis, sealing vessels and promoting 
neurite outgrowth. The capture of metal ions in turn would promote the aggregation of Aβ 
that deposits as diffuse amyloid. 
It has been postulated that, rather than Aβ itself, it may be the product of Aβ’s antioxidant 
activity, that is hydrogen peroxide (H2O2), to mediate toxicity as the levels of this oxidant rise 
with the accumulation of Aβ in the AD brain.  
 
2.3.5 Linking intracellular and extracellular Aβ 
A number of factors have been shown to modulate intraneuronal Aβ in animal models of AD, 
subsequently affecting also the extracellular Aβ pool. One of the most interesting 
observations is the effect of aging. For example, young 3xTg-AD mice accumulate both 
soluble and oligomeric Aβ within neuronal cell bodies, but the intraneuronal pool decreases at 
ages in which extracellular plaques manifest (Oddo et al., 2006b). This finding also parallels 
studies in human brain tissue, including that from patients with AD and DS (Mori et al., 2002; 
Wegiel et al., 2007). These studies suggest that the brain of patients with early stage AD 
might have more abundant intraneuronal Aβ, which then becomes extracellular as the disease 
progresses and neuronal death and lysis occur. Actually it has been demonstrated that 
intraneuronal Aβ levels in AD decrease as extracellular plaques accumulate. It may be that the 
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relatively low levels of intracellular Aβ in AD (compared with relatively high extracellular 
Aβ levels) are vital at first for the seeding of toxic oligomers giving rise to pathological 
events and further for extracellular plaque formation by secretion of these oligomeric species 
into the extracellular space. Secreted oligomers may also facilitate other pathological events, 
such as disruption of synaptic transmission. 
It is likely that both the intra- and extra- cellular Aβ pools contribute to cognitive decline in 
AD, and there is a complex relationship between these two pools and the various Aβ 
aggregation states. For example, 3xTg-AD mice that repeatedly learned to locate a hidden 
platform in the Morris water maze show improved cognition compared to animals that were 
not trained (Billings et al., 2007 ). More significantly, this learning alters the dynamics 
between intraneuronal Aβ, extracellular plaques and Aβ oligomerization. Learning increased 
intraneuronal and soluble Aβ, but decreased extracellular and oligomeric Aβ, with the net 
effect being improved cognition. Thus, the reduction in extracellular and oligomeric Aβ was 
highly beneficial, despite increases in intraneuronal Aβ in aged mice with established 
extracellular Aβ pathology. 
Other studies turned to Aβ immunotherapy to determine whether the intracellular and 
extracellular Aβ pools are related. Aβ immunotherapy has been used in various mouse models 
and quickly and effectively leads to clearance of the extracellular plaque load and improved 
cognition (Janus et al., 2000). In the 3xTg-AD model, removal of extracellular Aβ plaques is 
shortly followed by the clearance of intraneuronal Aβ (Oddo et al., 2004). Notably, as the 
pathology re-emerges, intraneuronal Aβ appears first, followed by the extracellular plaques. 
These observations show that clearance of extracellular Aβ with immunotherapy also leads to 
the indirect reduction of intraneuronal stores. This finding indicates that extracellular Aβ may 
originate from intraneuronal pools and that a dynamic equilibrium exists between the two 
pools, such that when extracellular pools are removed, intraneuronal pools are sequestered out 
of the cell. 
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Fig. 1 : APP trafficking in neurons (from O’Brian et al., 2011). Newly synthesized APP (purple) is transported 
from the Golgi down the axon (1) or into a cell body endosomal compartment (2). After insertion into the cell 
surface, some APP is cleaved by α-secretase (6) generating the sAPPα fragment, which diffuses away (green), 
and some is reinternalized into endosomes (3), where Aβ is generated (blue). Following proteolysis, the 
endosome recycles to the cell surface (4), releasing Aβ (blue) and sAPPβ. Transport from the endosomes to the 
Golgi prior to APP cleavage can also occur, mediated by retromers (5). 
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Fig. 2: Sequential cleavage of the amyloid precursor protein (APP) occurs by two pathways (from 
Thinakaran et al., 2008)  
(a) The APP family of proteins has large, biologically active, N-terminal ectodomains as well as a shorter C-
terminus that contains a crucial Tyrosine–Glutamic Acid-Asparagine-Proline-Threonine-Tyrosine (YENPTY) 
protein-sorting domain to which the adaptor proteins X11 and Fe65 bind. The Aβ peptide starts within the 
ectodomain and continues into the transmembrane region (red ). (b) Nonamyloidogenic processing of APP 
involving α-secretase followed by γ-secretase is shown. (c) Amyloidogenic processing of APP involving BACE1 
followed by γ-secretase is shown. Both processes generate soluble ectodomains (sAPPα and sAPPβ) and 
identical intracellular C-terminal fragments (AICD).  
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Fig. 3: Schematic diagram of APP and Aβ trafficking within a neuron (from Gouras et al., 2005).  
APP is trafficked from the ER, where some Aβ  may be generated, to the Golgi apparatus and then the plasma 
membrane (PM) where additional Aβ appears to be generated. Significant Aβ is produced in the trans-Golgi 
network (TGN). An important site of Aβ generation is in the endocytic pathway after APP internalization from 
the PM. Although APP localizes especially to the TGN, both APP and Aβ localize to vesicles within neuronal 
processes. In Alzheimer’s disease Aβ42 accumulates within MVBs of vulnerable neurons, especially within 
distal neuronal processes and pre- and post-synaptic compartments. 
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Chapter 3: Aβ in human cerebral amyloidosis 
3.1 Insights into Alzheimer’s disease (AD) 
3.1.1 Neuropathology of AD 
It was over a century ago that Alois Alzheimer admitted a 51-year-old patient, Auguste D., for 
progressive cognitive decline. Alzheimer’s histopathological observations of her brain 
following her death a few years later led to his realization that he was observing a unique 
clinical-pathological process, with a distinct and recognizable neuropathological substrate, 
that no long after was named Alzheimer’s disease (AD). 
Investigators at the beginning of the last century were intrigued by the origin of the deposition 
of a “peculiar substance” (also called “miliary necrosis”), eventually termed “plaques”, that 
along with neurofibrillary tangles (NFTs) appeared to characterize presenile and senile 
dementia. Alzheimer’s summary of his presentation in 1906 on the case of Auguste D. was 
published in 1907 and for the first time linked plaques and tangles with dementia. 
It is now widely recognized that the two primary cardinal lesions associated with AD are the 
NFTs and the senile plaque. 
NFTs are very difficult to be detected with the traditional morphological stain used by 
pathologists, hematoxylin and eosin. By and large, one of a variety of silver impregnation 
staining techniques, such as the modified Bielschowski or Gallyas technique, or the 
fluorochrome dye thioflavin S is typically employed to visualize neurofibrillary tangles. 
Additionally, there are a number of immunohistochemical approaches used to visualize 
neurofibrillary tangles. These have mostly employed antibodies directed against abnormally 
phosphorylated tau. 
With these special stains, within neurons with a pyramidal shape to the perikaryon, such as 
those of the cornu ammonis 1 (CA1) sector of the hippocampus and the layer V neurons in 
areas of the association cortex, the neurofibrillary tangles appear as parallel, thickened fibrils 
that surround the nucleus and extend toward the apical dendrite. When the neurofibrillary 
tangle occurs within a neuron with a more rounded configuration (e.g., neurons within the 
substantia nigra and locus ceruleus), the inclusion appears as interweaving swirls of fibers, 
and here it is called a globoid neurofibrillary tangle. 
Ultrastructurally, the neurofibrillary tangle is composed of abnormal fibrils measuring 10 nm 
in diameter that occur in pairs and are wound in a helical fashion with a regular periodicity of 
80 nm (Wisniewski et al., 1976). On the basis of these observations, such structures are 
generally called paired helical filaments. The primary constituent of the neurofibrillary tangle 
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is the microtubule-associated protein tau. The tau within neurofibrillary tangles is abnormally 
phosphorylated with phosphate groups attached to very specific sites on the molecule. The 
best established functions of tau are thought to be the stabilization of microtubules and the 
regulation of motor-driven axonal transport (Götz et al., 2006). It is known that the 
phosphorylation of tau causes its detachment from microtubules (Ballatore et al., 2007) and 
that soluble hyperphosphorylated tau contributes to neuronal disfunction before its deposition, 
negatively interfering with mitochondrial respiration and axonal transport (Götz et al., 2006). 
There are a number of other protein constituents associated with the neurofibrillary tangle, 
such as ubiquitin, cholinesterases and Aβ (Hyman et al., 1989) but tau is considered to be the 
critical constituent of most of these structures. 
The pattern of distribution of neurofibrillary tangles present in cases of AD is, for the most 
part, rather stereotyped and predictable. Severe involvement is seen in the layer II neurons of 
the entorhinal cortex, the CA1 and subicular regions of the hippocampus, the amygdala, and 
the deeper layers (layers III, V, and superficial VI) of the neocortex (Morrison and Hof, 
1997). Studies have shown that the extent and distribution of neurofibrillary tangles in AD 
cases correlate with both the degree of dementia and the duration of illness (Bierer et al., 
1995). However, it is also clear that other factors contribute to the production of the clinical 
features of the disease. Although the neurofibrillary tangle is considered a cardinal 
histopathological feature of AD, this neuropathological lesion may also be encountered in 
association with many other disease states (Wisniewski et al., 1979), such as postencephalitic 
parkinsonism, dementia pugilistica, type C Niemann-Pick disease, and amyotrophic lateral 
sclerosis/parkinsonism dementia complex of Guam. 
The other cardinal pathological lesion encountered in patients suffering from AD is the senile 
or neuritic plaque. Senile plaques are complex structures defined by the presence of a central 
core accumulation of a 4-kD protein with a β-pleated sheet configuration called Aβ. The 
predominant β-pleated sheet configuration of this protein confers its ability to bind the planar 
dye Congo red and produce birefringence when illuminated by polarized light; it thus 
conforms to the physical definition of an amyloid. 
The brains of aged individuals and cases of AD may also contain several forms of Aβ-
containing plaques. The senile or neuritic plaque has a central core of Aβ protein arranged in 
a radial fashion and is surrounded by a corona of abnormally formed neurites (or neuronal 
processes, either dendrites or axons). These abnormal or dystrophic neurites stain strongly 
with the same silver impregnation stains used to identify the NFTs, and ultrastructurally these 
structures contain dense bodies, membranous profiles, and packets of paired helical filaments. 
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In the periphery of the neuritic plaque, one commonly encounters reactive astrocytes of the 
macroglia, and, more frequently, one to several microglial cells. 
Microglial cells, which derive from mesoderm and comprise 5-10% of the glial population in 
the nervous system, have the potential to develop into macrophages and in fact they represent 
the first line of defense against invading pathogens or other types of brain tissue injury.  
Under pathological situations, these cells become activated, migrate, and surround damaged 
or dead cells, and subsequently clear cellular debris from the area.  In AD, microglia have a 
central role in the inflammation process. Actually inflammation in the AD brain is mediated 
by proinflammatory cytokines and would create a chronic and self-sustaining inflammatory 
interaction between activated microglia and astrocytes, stressed neurons, and Aβ plaques, as 
amyloid peptides and APP are potent glial activators. In some situations, the role of microglia 
has been found to be beneficial, since activated microglia can reduce Aβ accumulation by 
increasing its phagocytosis, clearance, and degradation (Frautschy et al., 1998; Qiu et al., 
1998).  Microglia can also secrete a number of soluble factors, such as the glia-derived 
neurotrophic factor (GDNF), which are potentially beneficial to the survival of neurons (Liu 
and Hong, 2003). 
Astrocytes, besides maintaining extracellular and neuronal environment, and stabilizing cell-
cell communications, also appear to be involved in the induction of neuroinflammmation. In 
AD they are known to be important for Aβ clearance and degradation, for providing trophic 
support to neurons, and for forming a protective barrier between Aβ deposits and neurons 
(Rossner et al., 2005). The presence of large numbers of astrocytes associated with Aβ 
deposits in AD suggests that these lesions generate chemotactic molecules that mediate 
astrocyte recruitment. Astrocytes are capable of accumulating substantial amounts of neuron-
derived Aβ42 positive material and other neuron specific proteins as a consequence of their 
debris-clearing role in response to local neurodegeneration. Astrocytes overburdened with 
these internalized materials can eventually undergo lysis, and radial dispersal of their 
cytoplasmatic contents can lead to the deposition of a persistent residue in the form of small, 
GFAP-rich, astrocytic amyloid plaques (Nagele et al., 2004). 
Under certain conditions related to chronic stress, however, the role of astrocytes may not be 
beneficial. A report suggests that astrocytes could also be a source for Aβ, because they 
overexpress β-secretase of APP (BACE1) in response to chronic stress (Rossner et al., 2005). 
On the basis of such a state-of-the-art it appears evident that the role of macroglia and 
microglia in AD still remains a matter of intense debate. 
30 
 
Through the use of immunohistochemical techniques with antibodies raised against portions 
of the Aβ molecule, it has been recognized that focal diffuse deposits of this amyloid protein 
may occur in the cerebral cortex in the absence of accompanying dystrophic neuritis 
(Yamaguchi et al., 1989). Such Aβ deposits  will also stain with the aforementioned silver-
based stains and are called diffuse plaques. Such plaques are very commonly encountered in 
the brains of elderly individuals and can be seen in relatively large numbers in the absence of 
any associated evidence of cognitive impairment (Morris et al., 1996). 
A third form of plaque, consisting of a dense core of Aβ not showing any accompanying 
dystrophic neurites, has also been identified. Such plaques have been called burned-out 
plaques and end-stage plaques and are considered to be the remnants of what were once 
neuritic plaques (Wisniewski et al., 1982). 
Senile plaques contain longer Aβ forms (having a total of 42 or 43 amino acids), while shorter 
Aβ forms (containing 40 amino acids) tend to accumulate within the leptomeningeal and 
cerebral cortical and cerebellar blood vessels, giving origin to a phenomenon of vascular 
amyloid deposition called congophilic angiopathy (Prelli et al., 1988). In this alteration Aβ 
accumulates in the walls of small arteries and arterioles of the leptomeninges and within the 
gray matter of the cerebral cortex. The accumulations of Aβ within the vessel walls do not 
appear to clog the vascular lumina or otherwise interfere with the vascular functions. 
However, when the degree of vascular involvement is severe, spontaneous vascular rupture 
may arise leading to focal accumulation of blood in the brain tissue. Hemorrhages tend to 
occur in the white matter of the frontal and/or occipital poles, are often small and multiple, 
and may be microscopic in size. If large (a relatively rare situation), they may be multiple and 
are commonly called lobar hemorrhages. Although rare, such lobar hemorrhages represent 
one of the few fatal intracerebral complications of AD. 
Furthermore, in the cerebral cortex of AD and DS affected patients, as well as in non-
demented individuals, Aβ extracellular deposits that were neither birefringent nor fluorescent 
nor associated with degenerating neurites, tangle-bearing neurons or congophilic vessels have 
been detected (Tagliavini et al., 1988). These deposits conceivably consisted of Aβ precursors 
lacking the molecular conformations of amyloid fibrils. Accordingly, they have been named 
preamyloid deposits, and they are likely supposed to be made up of APP itself or some of its 
early cleavage fragments (Giaccone et al., 1989). Preamyloid deposits have been reported to 
be ubiquitous in the brain grey substance (Ogomori et al., 1989), and are likely to give origin 
to senile plaques in the presence of vulnerable neurons (particularly at the level of the cortex 
and neostriatum) or to diffuse plaques in the brain regions where no permissive neurites are 
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available (Bugiani et al., 1989). In literature it has been reported that Aβ fibrillation 
intermediates, more than Aβ fibrils, seem to be involved in AD onset. Actually the number of 
plaques and the levels of insoluble Aβ in AD poorly correlate with the local extent of 
neuronal death and synaptic loss, or with cognitive impairment (McLean et al., 1999). On the 
other hand, the levels of soluble Aβ oligomers appear to strongly correlate with disease 
progression in animal models and AD subjects  (Haass et al., 2007). 
The major morphological counterpart to cognitive loss in AD is represented by a substantial 
loss in cerebral synaptic profiles. This aspect has been investigated by the quantification of 
immunohistochemical markers directed against synaptic proteins and by quantitative electron 
microscopy. A study reported a 45% loss of the extent of staining of presynaptic boutons in 
cases of AD in comparison with normal controls, finding that strongly correlates with the 
degree of functional impairment (Terry et al., 1991). 
It is clear that AD is a slowly progressive disorder whose lesions accumulate in the brain over 
a period of many years. 
It is not known long it may take before a sufficient extent of neuropathological damage occurs 
to produce a degree of functional impairment that might be clinically diagnosed, but it is 
likely to take many years for this to occur. Additional years are likely needed for the further 
progression from the early stages to the middle stages of the disorder. Within this perspective, 
researchers began to investigate the progressive stages of involvement of the brain in the 
course of AD and to speculate on what the earliest phases of the disease might look like. In 
1991, neuroanatomists Eva and Heiko Braak published a proposed sequence of progression of 
the neuropathology of AD, breaking the disorder down into 6 stages with increasing 
involvement of the brain (the so-called Braak and Braak stages). Braak and Braak stages 1 
and 2 show selective involvement by neurofibrillary tangles in the transentorhinal cortex. 
Stages I-II in the neuropathology of AD are considered preclinical and silent. They are 
followed by stages 3 and 4 with increasing limbic lobe involvement, with the final 2 stages 
(stages 5 and 6) showing the more typical widespread pattern of involvement in the neocortex. 
In stage VI, the process extends into the motor and sensory field. It is during stages III and IV 
that the first clinical symptoms of AD are frequently manifested. These Braak and Braak 
stages were initially developed by the evaluation of the pattern of neurodegenerative changes 
(predominantly neurofibrillary tangles) present in a series of 83 brain specimens derived from 
elderly individuals. They devised the stages by mapping out the extent and distribution of 
lesions in these brain specimens, but no associated clinical data were available from the 
patients from whom the samples were obtained. 
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Although it is clear that not all AD patients progress precisely along the stages they described, 
the Braak and Braak stages do represent a useful concept and have provided a format for 
neuropathologists to use in evaluating the relative stage of development of the disease. 
 
3.1.2 Neuropathological changes in the normal human brain aging: blurring 
the divide with AD 
The histological alterations upon which the neuropathological diagnosis of AD is made may 
also be seen, to some degree, in the brains of elderly individuals who during life had shown 
normal cognitive function. These changes are generally much fewer than in AD, and occur in 
restricted regions of the cerebral cortex, in the absence of significant cognitive decline. It is 
now well established that NFTs, senile plaques and synaptic loss, the main pathological 
hallmarks of AD, can often be found in the brains of non-demented elderly individuals 
(Tomlinson et al., 1968; Ulrich J., 1985). Actually it has been reported that the majority of 
elderly people display NFT formation in the hippocampal formation even in absence of 
cognitive impairment or with very mild memory impairment (West et al., 1994; Bierer et al., 
1995). Furthermore, senile plaques may appear early in the neocortex of intellectually 
preserved individuals, whereas the hippocampus is relatively spared by senile plaque 
formation and by the onset of the degenerative process (Hof et al., 1990, 1992). Synaptic 
alterations and neuronal loss have been found in the neocortex of elderly non-demented 
individuals, suggesting an age-dipendent mechanism for the loss of synapses in the neocortex 
(Masliah et al., 1993). 
The examination of a large sample of 1144 non-demented autopsy cases, reported by Hof et 
al. (1996), always evidenced the involvement of layer II of the entorhinal cortex with NFT 
formation, whereas the CA1 field of the hippocampus and the subiculum were less 
consistently affected. Moreover the inferior temporal cortex (Brodmann’s area 20) appeared 
particularly prone to develop NFTs in intellectually preserved elders, and such a finding was 
supposed to prelude the emergence of the neuropsychological deficits characteristic of AD. 
Regarding the detection of senile plaques, Hof et al. (1996) described its occurrence with an 
increasing prevalence concurrently with increasing age in non-demented people. A positive 
correlation between age and SP prevalence was highlighted in the inferior temporal, superior 
frontal and occipital cortices. It has been shown that at least 20% of cognitively normal 
elderly evidence Aβ neuropathology upon autopsy (Price and Morris, 1999; Bennett et al., 
2006).  
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With respect to senile plaque counts, several studies have indicated that there is no 
relationship between their amount, time of appearance and distribution and the phenomena of 
neurodegeneration or cognitive impairment, as is the case in younger populations (Delaère et 
al., 1993; Giannakopoulos et al., 1993). Actually, as fibrillary plaques seem to correlate 
poorly with neurodegeneration, investigators began to turn their focus to the importance of 
soluble oligomers and the role of preamyloid and cerebrovascular deposits. Extensive 
numbers of preamyloid lesions can be found in aged individuals, even with no reported 
clinical symptoms (Delaere et al., 1990; Crystal et al., 1993), in the form of scattered deposits 
of amyloid fibril precursor occurring in both cerebral cortex and subcortical grey structures 
(Bugiani et al., 1990). It has been demonstrated that the deposition of amyloid fibril 
precursors in the neuropil is closely related to presynaptic terminals, although whether the 
former precedes or follows the development of presynaptic terminal changes is still 
undetermined (Bugiani et al., 1990). 
Preamyloid deposits are amorphous, roughly spherical areas immunoreactive with anti-Aβ 
antibodies, having irregular borders, and are associated with few or no dystrophic neurites. 
Preamyloid deposits, unlike amyloid, are not stained by Congo red or thioflavine S 
(Wisniewski et al., 1989; Yamaguchi et al., 1991). Ultrastructurally, these deposits are mainly 
nonfibrillar. 
The apparent lack of associated cerebral dysfunction from preamyloid lesions can be 
correlated with in vitro studies using Aβ synthetic peptides, where it has been suggested that 
toxicity is dependent on the presence of a fibrillar, predominantly β-sheet conformation (Pike 
et al., 1993; Lorenzo et al., 1994). The Aβ 17-42 isoform has been reported to be a major 
component of preamyloid deposits in AD (Gowing et al., 1994) and DS (Lalowski et al., 
1996). 
Often the recognition of the extent of involvement in certain brain areas by AD characteristic 
lesions is required for the neuropathologist to declare that AD was the cause of a patient’s 
cognitive impairment. At times, this may involve subtle distinctions that require considerable 
experience and expertise, and at other times, the honest neuropathologist may be required to 
state that this diagnosis can be rendered with only a degree of probability and not certainty. 
This is particularly true when one is examining the brains of subjects dying within the oldest-
old age range. In individuals dying at an extremely old age, the overlap of neuropathological 
changes between those found with severe dementia and those with intact cognitive function is 
extensive, and the distinction may be very difficult. 
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Indeed, correlations between the extent and distribution of senile plaques and neurofibrillary 
tangles are currently undergoing detailed scientific study using brain specimens derived from 
individuals in large cohorts of advanced elderly subjects who underwent rigorous 
neuropsychological studies (Haroutunian et al., 2008). 
 
3.1.3 Genetic aspects underlying AD 
AD is the most common irreversible, progressive cause of dementia. It is characterized by a 
gradual loss of memory and cognitive skills. 
AD accounts for over 50% of all dementia cases, and it presently affects more than 24 million 
people worldwide. The incidence increases from 1% between the ages of 60 and 70 to 6% to 
8% at the age of 85 years or older and is likely to increase as a greater proportion of the 
population ages. So the prevalence and incidence of AD suggest that age is the most known 
risk factor. The disease is divided into 2 subtypes based on the age of onset: early-onset AD 
(EOAD) and late-onset AD (LOAD). 
Early-onset AD accounts for approximately 1% to 6% of all cases and ranges roughly from 30  
to 60 or 65 years. However, LOAD, which is the most common form of AD, is defined as AD 
with an age at onset later than 60 or 65 years. Both EOAD and LOAD may occur in people 
with a positive family history of AD. Approximately 60% of EOAD cases have multiple cases 
of AD within their families, and 13% of these familial EOAD are inherited in an autosomal 
dominant manner with at least 3 generations affected. With the exception of a few autosomal 
dominant families that are single-gene disorders, most AD cases appear to be a complex 
disorder that is likely to involve multiple susceptibility genes and environmental factors. 
Overall, more than 90% of patients with AD appear to be sporadic and to have a later age at 
onset of 60 to 65 years of age (LOAD). Although some studies support the existence of a 
genetic component in LOAD, no causative gene has been yet identified, except the 
apolipoprotein E (APOE) gene. The risk allele is the isoform ԑ4, but many carriers live into 
their 90s suggesting that there many others genetics and environmental risk factors associated. 
Around 1980s, three principal genes were identified in association with early onset  AD, APP, 
presenilin 1 (PSEN1), and presenilin 2 (PSEN2). Identification of the APP gene was made 
possible by the seminal work of Glenner and Wong  who, in 1984, determined a partial amino 
acid sequence of a peptide isolated from AD brain cerebrovascular amyloid.   
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3.1.3.1 EOAD and genes involved 
 
The APP gene was then mapped to chromosome 21q. The predicted protein, designated APP, 
is an ubiquitously expressed, single-pass transmembrane protein that contains an internal 39–
43 amino acid sequence. Aβ peptides are generated from APP by two endoproteolytic 
cleavages catalyzed by β- and γ-secretases; α-secretase catalyzes endoproteolysis of APP 
within the Aβ sequence. 
Aβ peptides are the primary component of amyloid deposits that form in the brain 
parenchyma (called ‘‘plaques’’) and in the walls of cerebral vessels, in the latter case giving 
origin to the pathological condition called ‘‘cerebral amyloid angiopathy’’(CAA); both Aβ 
plaques and vascular deposits are key features of AD neuropathological changes. To date, 24 
APP single nucleotide mutations are known to cause AD. 
APP can encode multiple isoforms, the longest of 750 amino acids and all AD mutations are 
clustered within a 54 amino acids sequence near or within the segment that encode Aβ  
peptide. One of this is the Swedish mutation, a double sostitution changing the two amino 
acids immediately before the Aβ sequence (lysine-methionine is replaced by asparagine-
leucine). The Swedish mutation is outside the Aβ sequence, so the peptide produced is 
normal, even if its quantity is two to threefold higher than that produced by non mutated APP, 
presumably because the efficiency of the β-secretase cleavage is affected. The implication is 
that an excess of Aβ production is sufficient to cause AD. This conclusion is supported by the 
longstanding observation that individuals with trisomy 21 (DS affected) develop extensive 
AD neuropathologic changes that can occur very early in life, until their 40s. 
Other APP mutations are located near the C-terminal Aβ peptide, and the most common is 
p.Val717Ile. These mutation affects the activity of γ-secretase, the cleavage of which 
normally reduces APP to a 40 amino acid peptide (Aβ40), with smaller amounts of Aβ that is 
42 amino acids long (Aβ42). APP mutations at the C-terminal end of Aβ shift proteolysis to 
produce more Aβ42 at the expense of Aβ40, resulting in an increased Aβ 42/ Aβ 40 ratio but 
not necessarily changing the total amount of Aβ peptides formed. Αβ42 is more 
amyloidogenic and more prone to aggregate than shorter Aβ forms. These data were the first  
to suggest that Aβ aggregation is a key event to AD pathogenesis. 
Another mutation of note is p.Glu693Gly, also known as the Arctic mutation. This amino acid 
change within Aβ does increase the aggregation rate of the mutant peptide, adding to the 
evidence that APP mutations can result in Aβ peptides with altered aggregation properties and 
that this process is critical to AD pathogenesis. 
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Several studies have demonstrated variation in the most characteristic AD neuropathological 
features among patients with APP mutations. At the time of autopsy, patients with APP 
mutations tend to have greater amounts of neocortical senile plaques than patients affected by 
‘‘sporadic’’AD. The ratio of accumulated Aβ42/Aβ40 may be higher in cases of autosomal 
dominant AD in respect to APP mutated cases, but there is a limited number of examples and 
a wide variation in the results. In addition to variation in the amount of the peculiar 
neuropathological traits of AD, APP mutations are also associated with morphologic variants. 
Several APP mutations have been associated with variation in the structure of Aβ deposits. 
These include the p.Ala692Gly (Flemish) APP mutation that is associated with large, dense 
plaques and the p.Glu693Gly (Arctic) APP mutation with ring-like plaques. CAA is a 
common feature of AD caused by mutations in APP. The p.Asp694Asn (Iowa) and 
p.Ala713Thr mutations are associated with exceptionally severe CAA in the context of the 
core neuropathological features of AD. The p.Glu693Gln (Dutch) APP mutation produces 
CAA without significant accumulation of the core features of AD; in the affected individuals, 
progressive cognitive impairment is linked to vascular brain injury. Several cases of AD 
caused by mutations in APP also have Lewy bodies dementia (LBD), which is detectable by 
histochemical stains of pigmented brainstem neurons and can be assessed also in other brain 
regions, including the limbic structures and the neocortex, by α-synuclein immunoreactive 
Lewy bodies and Lewy neuritis. 
The other two genes involved in EOAD are presenilin 1 (PSEN1) and presenilin 2 (PSEN2), 
located on the chromosome 14q. 
Over 180 mutations in PSEN1 are known to cause autosomal dominant AD. Penetrance of 
PSEN1 mutations is complete by 60–65 years of age, meaning that all mutation carriers 
develop early-onset AD. Fewer than 15 known mutations in PSEN2 can also cause early-
onset autosomal dominant AD, but penetrance is more variable than PSEN1. 
PSEN1 and PSEN2 encode closely related proteins that are part of the γ-secretase complex. 
Either PSEN1 or 2, together with nicastrin, APH1, and PEN2, form a complex that catalyze 
the cleavage of a number of different membrane proteins at sites embedded in the lipid 
bilayer. In the case of APP, the presenilin-containing γ-secretase catalyzes endoproteolysis at 
the C-terminal end of the Aβ-peptide sequence. This proteolytic event, along with a second 
cleavage at the N-terminal end of this sequence, is required for production of Aβ-peptide from 
APP. 
The γ-Secretase containing mutation-altered presenilin still catalyzes cleavage of APP, but the 
proteolytic site is altered. Normal γ-secretase yields predominantly Aβ40 with smaller 
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amounts of Aβ42. Mutant γ-secretase produces more Aβ42, a result consistently obtained 
across multiple studies. As noted previously, Aβ42 is more amyloidogenic and more prone to 
aggregate than Aβ40. While the mutated genes that cause early-onset AD inform about 
molecular mechanisms, they account for only a fraction of AD cases. As with APP mutations, 
individuals who died from AD caused by mutations in PSEN1 or PSEN2 tend to have a 
greater amount of neocortical senile plaques and a shift toward a higher Aβ42/Aβ40 ratio  
than patients who had ‘‘sporadic’’ AD, although again these data derive from relatively few 
examples with wide variation even within the same family. 
The relationship between PSEN1 or PSEN2 mutations and neurofibrillary degeneration is 
more complex. Actually there is no difference between the amount of neurofibrillary tangles 
present in AD resulting from PSEN1 or PSEN2 mutations and in ‘‘sporadic’’AD. A PSEN1 
mutation, given by a substitution in exon 8 (leucine271valine) that results in transcripts 
lacking exon 8, has been associated with lack of neuritic change in senile plaques. In contrast, 
increased accumulation of tau species other than neurofibrillary tangles has been reported in 
some cases caused by a PSEN1 mutation. 
PSEN1 mutations also are associated with a morphologic variant in Aβ plaques: the so-called 
cotton wool plaque. Cotton wool plaques occur in the same regions of brain as senile plaques 
and have been associated with multiple PSEN1 mutations. Cotton wool plaques typically have 
limited fluorescence following staining with thioflavin S and tend to be more immunoreactive 
for Aβ42 than for Aβ40. It is important to stress that although highly characteristic of PSEN1 
mutation, cotton wool plaques also have been reported in apparently sporadic AD. 
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3.1.3.2 LOAD and genes involved 
 
The majority of AD patients are late-onset AD (LOAD) cases with risk approximately 
doubling every 5 years after age 65. Except for a handful of PSEN2 mutation carriers, LOAD 
very often  results from  multiple genes contributing to susceptibility or risk. 
To identify these multiple interacting genes, new technologies have been very important, 
especially  a method called genome-wide association studies (GWAS). This method has led to 
an explosion in the discovery of genetic susceptibility for a large number of diseases, disease-
related traits, and associated phenotypes. For neuropathological affections, successful GWAS 
results have been reported for AD, Parkinson’s disease, amyotrophic lateral sclerosis and 
multiple sclerosis. 
Late generation genotyping platforms permit interrogation of most of the genome for disease-
associated variation in a single experiment, thanks to arrays containing assays to screen from 
600,000 to 2.5 million single nucleotide polymorphisms (SNPs). Thus genotyping platforms 
provide key informations on linkage disequilibrium or correlation between neighboring SNPs, 
and are very useful in comparing the different genetic profile of case and controls. Thanks to 
this new technique the ApoE and later Sorl1 genes have been identified as key genes in 
LOAD.  
The apolipoprotein E (ApoE), the gene of which is located on chromosome 19q, is a protein 
originally extensively studied for its crucial role in lipid metabolism, but then recognized as a 
pleiotropic molecule with important functions in lipid transport, Aβ trafficking, synaptic 
function, immune regulation, and intracellular signaling. ApoE, like other apolipoproteins, is 
a protein component of lipoprotein particles that binds to the cell surface receptors. In humans 
ApoE is present in three isoforms, given by the ԑ2, ԑ3, and ԑ4 alleles encoding 299 amino 
acid-long protein isoforms. This polymorphism is unique to man and it has been proposed to 
have evolved as a result of adaptive changes to diet. In 1991, Pericak-Vance and colleagues, 
using family-based methods, identified a genetic linkage between AD and a region of 
chromosome 19 that harbors ApoE. 
The key polymorphism associated to AD is in the three allele isoforms ԑ2, ԑ3, and ԑ4. These 
alleles represent haplotypes of two SNPs in the coding region of ApoE. The ԑ2 allele encodes 
a cysteine (Cys) both at amino acid position 112 and at position 158. Allele ԑ3 encodes a Cys 
at 112 and an arginine (Arg) at 158, while the ԑ4 allele encodes an Arg both at 112 and at 158. 
The ԑ4 allele is the ancestral and high-risk form, the ԑ3 allele is the most common in humans 
and the neutral allele, and the ԑ2 allele is associated with decreased risk of AD. 
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On a population level, people with an ԑ4 allele have lower average onset age and those with 
an ԑ2 allele have a higher average onset age for AD. The AD risk associated with these alleles 
is additive. A person with a genotype of ԑ4/ ԑ4 is at higher risk than someone with an ԑ3/ ԑ4or 
ԑ2/ ԑ4 genotype. Likewise, ԑ2/ԑ2 genotype is more protective than genotypes where only one 
ԑ2 allele is inherited. Many publications reported the risk associated with this pattern, 
associated with all ethnic groups and observed that amyloid plaques had ApoE 
immunoreactivity  and that ApoE expression is up-regulated in activated astrocytes in AD 
brain; it was the genetic discovery that clearly linked ApoE isoforms to AD pathogenesis. 
Although the risk associated with the isoform ԑ4 is clear, the pathogenetic mechanism still is 
not well determined. As the major apolipoprotein of the chylomicron in the brain, ApoE binds 
to a specific receptor and works through receptor mediated endocytosis to rapidly remove 
chylomicron and VLDL remnants from circulation; this process is essential for the normal 
catabolism of triglyceride-rich lipoprotein constituents. In the brain, lipidated ApoE binds 
aggregated Aβ in an ApoE isoform-specific manner, with Apoԑ4 being much more effective 
than the Apoԑ3 isoform. 
Researchers have also proposed that the more efficient binding process of Apoԑ4 enhances the 
deposition of the Aβ peptide. ApoE genotypes also influence onset ages in carriers of PSEN1 
or PSEN2 mutations. Less compelling evidence suggests that ApoE genotypes also affect age 
of onset in subjects carrying APP mutations. Alternatively, ApoE might also bind Aβ and act 
as a chaperone to influence the rate of Aβ fibrillogenesis.  
Another hypothesis is that ApoE lipid particles bind Aβ and clear the extracellular peptide by 
endocytosis and subsequent degradation. In each of these proposed mechanisms, the 
functional difference between the ԑ2-, ԑ3-, and ԑ4-encoded isoforms is the basis of risk 
associated with ApoE. Early work suggested that polymorphisms within the promoter of 
ApoE influence risk, though these findings were not replicated in large data sets. A recent 
publication, using a modest sample size, suggests that a poly-T track in TOMM40, the gene 
adjacent to ApoE affects AD onset age. The poly-T track in TOMM40 is variable in length; 
long poly-T length alleles associated with the ԑ3 ApoE allele were reported to have an earlier 
onset age than short poly-T track alleles. In subsequent work using substantially larger 
samples, this relationship between poly-T track length and onset age was not replicated, and 
when ApoE genotypes were accounted for, there was no significant association to TOMM40 
(Schellenberg et al., 2012). 
Studies in knock-out mice also confirm the importance of ApoE in AD pathogenesis. Brain 
cells from APOE knockout (APOE_/_) mice are more sensitive to excitotoxic and age-related 
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synaptic loss, and Aβ-induced synaptosomal dysfunction in these mice is also enhanced 
compared to control animals. When human ApoE isoforms (Apoԑ3 and Apoԑ4) are expressed 
in APOE_/_ mice, the expression of Apoԑ3, but not Apoԑ4, is protective against age-related 
neurodegeneration and Aβ toxicity. In addition, astrocytes from APOE _/_ mice that express 
human Apoԑ3 release more cholesterol than those expressing Apoԑ4 (Buttini et al., 1999); this 
suggests that ApoE isoforms may modulate the amount of lipid available for neurons. 
There are also clinical evidences of the correlation between Apoԑ4 genotype and Aβ 
accumulation, as showed  in many clinical trials where this correlation was identified; in one 
of these (Christensen et al., 2010) 20 patients with AD and 10 controls were examined to 
correlate age, sex and ApoE genotype with accumulation of Aβ peptides; the clear result was 
that Apoԑ4 genotype was highly correlated with the intensity of the Aβ stainings. 
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Chapter 4: Evidence of β-amyloid and NFTs accumulation in 
the brain of animal species 
 
A wide range of changes has been described in the ageing brain of many species with the 
most detailed investigations reported about dogs, cats and monkeys. Among the age-
associated changes in animal brains, the detection of senile plaques and β-amyloid deposits 
has frequently been reported in the framework of retrospective neuropathological studies. 
Regarding dogs, canines have always represented a good model in neurological research, as 
the detection of their age-related behavioural changes is rather easy for both pet owners and 
veterinarians, they are very easy to handle and their  life span is moderate, from about 12 to 
20 years. Furthermore, canines share both the same environment and often the same food as 
man, therefore they may provide a unique model for studies of human aging. There are many 
evidences in the canine brain that support the hypothesis that β-amyloid plays a central role in 
age-related cognitive dysfunction and neuropathology. Amyloid appears to build up initially 
in and around neurons and is present within apical and basal dendrites. Furthermore β- 
amyloid is deposited uniformly in some synaptic terminal fields that show a predilection for 
extensive plaque formation in AD. Probably in the dog β-amyloid accumulation precedes 
plaque formation. With time, early diffuse plaques form within these terminal fields and 
around β-amyloid laden neurons. At this early stage, glial cells do not appear to be associated 
with the developing plaque. Thus in the canine model neurons appear to be the initial source 
of β-amyloid deposition (Cummings et al, 1995). 
More recent studies have clarified the role of β-amyloid in the neurodegenerative phenomena 
of dog brains. In this species three major types of plaques have been identified, depending on 
their stage progress: diffuse (non-β-sheet), primitive (β-sheet lacking a central core of 
amyloid) and neuritic (β-sheet containing a central core of amyloid and extensive reactive 
astroglia). It is believed that the progression of plaque formation proceeds through specific 
identifiable stages, from diffuse to the neuritic subtype, that is characteristic of the end-stage 
AD in humans. Extensive immunohistochemical and fluorescence staining analyses 
demonstrate that the plaque most consistently observed in the canine brain is of the diffuse 
subtype, although occasional occurrence of mature (primitive or neuritic) plaques have been 
shown in some studies (Aristotelis et al, 2002). 
As in humans, the different plaque subtypes have a different location in the dog brain areas, 
giving rise to an uneven distribution. The distribution is uneven both at the immediate cellular 
level and the cerebrocortical surface level. In the former instance, at a cellular level a site that 
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has been known to selectively accumulate Aβ deposits is the axonal synaptic field of neurons, 
whereas at a neuroanatomical level the first site of Aβ accumulation in the dog brain is the 
prefrontal cortex, followed by the parietal, the entorhinal and the occipital. The observed 
cognitive decline in the aged dog might be probably ascribed to the phenomena of Aβ 
accumulation in these regions. The forms of Aβ detected in the plaques are of different 
lengths, depending on the cleavage of APP. The most common form found in the dog brain 
seems to be Aβ1–42, that is constitutive of the diffuse plaques, whereas mature (primitive or 
neuritic plaques) are predominantly formed by the Aβ1–40. This hypothesis is supported by 
another work (Borras et al, 1999) reporting a fewer amounts of amyloid plaques detected in 
aged dogs brains compared to other studies, as the anti-Aβ antibody employed recognized the 
Aβ40 peptide but not the Aβ42 isoform. This finding likely undirectly confirms that the 
diffuse plaques are the predominant type in canines. 
Another notable feature of diffuse plaque deposition in the dog brain in comparison to man 
relates to their spread and number: interestingly, in those cases where the canine cognitive 
decline can only be regarded as pre-AD stage, the amount of cerebral plaques detectable 
equals or might even exceed that characterizing the most severe cases of AD in humans. 
An additional difference between dogs and human beings regards glial reactivity within brain 
plaques: unlike AD affected patients, canines are devoid of any infiltrating hyperactive glia 
within diffuse plaques; instead, astrocytic reactivity in close relation to plaques has been 
reported (Aristotelis et al, 2002). 
A surprising characteristic is the integrity of the intra-plaque neurons in the canine brain. This 
is probably due to the fact that Aβ exerts its neurotoxic effects only when found in its 
aggregated β-pleated-sheet form, whereas it is neurotrophic when not aggregated. 
Regarding the presence of NFTs in the dog brain, they have not been reported in literature 
even using several antibodies against abnormally phosphorylated tau. This could be an 
interesting point for understanding the association between the accumulation of β-amyloid 
with selective behavioral dysfunction in the absence of NFTs. 
Cats have been proposed  as another candidate animal model of AD. A comparison of the β-
amyloid deposition processes between dogs and cats of different ages has been reported by 
Takeuchi et al. (2008). Cerebral Aβ deposition was first detected at an age of 7 years and 9 
months in the dog and at 10 years in the cat; quantity and frequency of Aβ deposits seemed to 
increase with age in both species. Whereas Aβ deposits were observed in the cerebral cortex, 
hippocampus, and meningeal vessel walls in dogs, in the cats examined Aβ deposits affected 
the cerebral cortex and the hippocampus, but not the meningeal vessel walls. In both dogs and 
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cats Aβ deposition in the brain parenchyma occurred as diffuse plaques, unlike the well 
developed and circumscribed plaques that are typical of humans. 
β-amyloid accumulation in cats has been reported also in a study by Head et al. (2005) which 
demonstrated that Aβ1–40 isoform was not present in any of the cat brains examined 
immunohistochemically. In contrast, 4G8 revealed the presence of plaques of  the diffuse 
type. Aβ deposits in the cat brain were large and even more diffuse than those described in 
dogs. Interestingly two of the five aged cats examined in that study showed 
hyperphosphorylated tau. The tau isoform detected did not present the phosphorylation at 
residue Thr181 and Thr205 as in humans, suggesting the presence of a different tau isoform 
compared to man. However NFTs have not been described in those cat brains, however the 
aforementioned report could be an example of a possible pre-tangle formation process 
occurring in older cats. 
Other animal models that have been particularly studied because of their great genetic 
similarities with man are the non-primate species. Senile plaques and vascular amyloid have 
been mainly described in chimpanzees and macaques (Gearing et al., 1994), in the gorilla 
(Kimura et al., 2001), in baboons (Ndung’u et al., 2011) and squirrel monkeys (Walker et al., 
1990). 
In a study by Gearing et al. (1994) comparing the neuropathological findings of aged 
chimpanzees and rhesus monkeys both the species displayed amyloid deposition in meningeal 
and cortical vessels walls and amyloid plaques in the brain parenchyma. Whereas in 
chimpanzees amyloid plaques were mainly of the diffuse type and neuritic plaques were 
seldom discovered, neuritic plaques were the predominant subtype in the two oldest rhesus 
monkeys examined. 
Cerebral amyloid deposits were reported by Kimura et al. (2001) also in a male middle-aged 
(44-year-old) Western Lowland gorilla. The senile Aβ-42 positive plaques found in the 
cerebral neocortex were of the diffuse type, showing filamentous and amorphous structures 
with an irregular margin. NTFs were investigated by immunostaining for tau2, but were not 
detected. It might be hypothesized that the diffuse plaques described in such middle-aged case 
would have evolved into senile plaques with time, as happens in man. 
Aβ peptides deposition has been investigated also in the brain of different subspecies of 
baboons ranging from 18 to 28 years (Ndung’u et al., 2011). Similarly to the aforementioned 
species, brain plaques detected were of the diffuse non-fibrillar type. Neocortical plaques 
were distributed in layers 3-5 frequently involving a microvessel. In the hippocampus they 
were distributed largely in the pyramidal cell layers. Amyloid plaques in baboons were of 
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similar size and regional distribution as in the rhesus monkey. In addition to amyloid deposits, 
a faint immunolabelling of hyperphosphorylated tau in the oldest baboons was found. This 
finding reflects the situation in humans, where NFTs develop in the last stages of the diffuse 
plaque formation process. 
Squirrel monkeys represent a peculiar species as in their brain amyloid is associated primarily 
with both intracerebral and meningeal capillaries, and it occurs to a lesser degree than the 
other non-primates as parenchymal deposits. The latter consist mainly of diffuse plaques, but 
also senile plaques have been reported to occur in squirrel monkeys (Walker et al., 1990). 
In literature few but interesting case reports about β-amyloid and NFTs brain deposition are 
available also regarding some wild animal species, among which even bears and the 
wolverine are encountered. Diffuse and senile plaques were detected in the cerebral cortex of 
an American black bear (Uchida et al., 1995). Senile plaques were mainly localized in the 
molecular layer of the cortex, while diffuse plaques were also described in the caudatum, 
hippocampus and olfactory bulbs. Additionally, a supposed specific neuropathological feature 
of AD, i.e. the presence of diffuse plaques in the cerebellar molecular layer, was described in 
the case examined. Despite the severity of amyloidosis, NFTs were not detected. 
In a study on the brain of a wild old aged carnivore, the wolverine (Gulo gulo), phenomena of 
β-amyloid deposition in the form of vascular deposits as well as both diffuse and neuritic 
cerebral plaques were described. NFTs appeared in large amounts at the cerebral cortex and 
hippocampal level (Roertgen et al., 1996). 
The findings of Aβ and NFTs cerebral deposition reported in literature to date are mainly 
related to domestic carnivores and wild omnivores, and few data are available at present about 
domestic and wild large herbivores. Within this latter category of animals limited descriptions 
have been published regarding the horse (Capucchio et al., 2009), the sheep (Nelson et al., 
1994), the elephant (Cole et al., 1990) and the camel (Nakamura et al., 1995). Among these 
species the presence of NFTs has been reported in sheep, whereas it was not shown in the 
brain of the elephant and the camel. In the horse, clear evidences of Tau accumulation were 
detected, but Tau-positive hippocampal neurons observed in the study by Capucchio et al. 
(2009) did not express hyperphosphorylated Tau (AT8), indicating that the accumulated Tau 
was not hyperphosphorylated at position S202. However, phosphorylation at other amino acid 
residues could not be ruled out. So the conclusion was that non-phosphoryled-S202 Tau 
accumulates in some hippocampal neurons in a non-neurofibrillary tangle manner, perhaps 
due to axonal transport deficiencies occurring in ageing. 
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The sheep and the elephant appeared to be spare of cerebral β-amyloid deposition; instead, 
diffuse β-amyloid plaques were found in the brain of horses (Capucchio et al., 2009), even if 
sporadically, characterized by the accumulation of the N-truncated Aβ42 isoform and no 
Aβ40, similarly to the dog. 
On the histopatological examination of the brain of an aged 20-year-old camel (Nakamura et 
al., 1995) senile plaques were detected. They were mostly of the diffuse type, but with a more 
clearly demarcated border than those seen in aged dogs. Only a few primitive plaques were 
detected using an Aβ-40 antibody. Plaques were mainly distributed throughout the cerebral 
cortex, whereas they were not detected in the hippocampus and in the cerebellar cortex. 
The camel case represents a very interesting case as it is the first herbivorous animal in which 
the presence of β-amyloid plaques has been detected on the basis of proper histopathological 
and immunohistochemical examinations. 
Hence dietary habits were supposed to be important factors in plaques formation. However, 
evidence had already been provided that herbivorous species, such as cows and sheep, could 
develop senile plaques, since the amino acid sequence of their β-protein is identical to that of 
animals usually affected by senile plaques, although their nucleotide sequence is different 
(Nakamura et al., 1995). 
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Chapter 5: Materials and Methods 
 
5.1 Animal and tissue collection 
 
Brain sections of frontal cortex, hippocampus, cerebellum and brainstem samples obtained at 
necroscopy from 102 cattle of various breeds (Piemontese, Podolica, Friesian and mixed 
breed), ranging from fetuses to cattle 240 months of age, were investigated (see Table 2 for 
details). Fifty cattle were healthy at death while fifty-two had shown neurological signs in vita 
and they had undergone neuropathological examination at Istituto Zooprofilattico of Turin 
(CEA): in 23 of these animals no abnormalities had been detected on neuropathological 
examination while 29 of them presented a neuropathological framework attributable to 
different categories of diseases: the majority belonged to the group of inflammatory diseases, 
the remaining to the groups of toxic-metabolic or others diseases, like food poisoning. 
Because of their age at death, some of them were tested with screening routine test for PrP
Sc
, 
but resulted negative. 
At necropsy, the brain was removed and then a paramedian cut was done. 
The small part was frozen at - 80°C until biochemical studies were performed, and the other 
was ﬁxed in 10% buffered formaldehyde solution for histological and immunohistochemical 
analysis. 
 
ID animal age (months) Breed Health status Neuropathological 
        alterations 
101685/09 8 m  Frisona healthy absent  
102648/09 8 m  Frisona  healthy absent  
bov 13 8 m  Frisona  healthy absent  
bov 14 8 m  Frisona  healthy absent  
bov 15 8 m  Frisona  healthy absent  
bov 17 8 m  Frisona  healthy absent  
bov 18  8 m  Frisona  healthy absent  
bov 19 8 m  Frisona  healthy absent  
bov 20 8 m  Frisona  healthy absent  
bov 12 8 m  Frisona  healthy absent  
bov 22 8 m  Frisona  healthy absent  
bov 16 8 m  Frisona  healthy absent  
101609/09 8 m  Frisona  healthy absent  
101670/09 8 m  Frisona healthy absent  
47 
 
102487/09 8 m  Frisona  healthy absent  
102639/09 8 m  Frisona  healthy absent  
102448/09 8 m  Frisona  healthy absent  
16685 180 m  Podolica  healthy absent  
16686 192 m  Podolica  healthy absent  
16560 180 m  Podolica  healthy absent  
16476 156 m  Podolica  healthy absent  
16609 120 m  Podolica  healthy absent  
16561 132 m  Podolica  healthy absent  
16513 156 m  Podolica  healthy absent  
16674 120 m  Podolica  healthy absent  
16530 132 m  Podolica  healthy absent  
16713 120 m  Podolica  healthy absent  
16532 144 m  Podolica  healthy absent  
16559 180 m  Podolica  healthy absent  
16531 168 m  Podolica  healthy absent  
16489 156 m  Podolica  healthy absent  
16474 156 m  Podolica  healthy absent  
16687 132 m  Podolica  healthy absent  
15795 240 m Podolica  healthy absent  
15745 180 m  Podolica  healthy absent  
16047 180 m  Podolica  healthy absent  
15903 120 m  Podolica  healthy absent  
15747 180 m  Podolica  healthy absent  
16475 192 m  Podolica  healthy absent  
16610 168 m  Podolica  healthy absent  
16048 180 m  Podolica  healthy absent  
16050 36 m  Podolica  healthy absent  
15851 180 m  Podolica  healthy absent  
16673 13 m  Podolica  healthy absent  
16991 199 m  Podolica  healthy absent  
17013 112 m  Podolica  healthy absent  
17014 194 m  Podolica  healthy absent  
17407 184 m  Podolica  healthy absent  
17408 89 m  Podolica  healthy absent  
17463 123 m  Podolica  healthy absent  
113516/04 84 m  Pezzata Rossa diseased present  
16602/10 84,5 m  Piemontese  diseased present  
110308/07 60 m  Piemontese diseased present  
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142364/04 72 m  cross-breed  diseased present  
116461/08 foetus  Piemontese  diseased present  
685/03 36 m  Valdostana diseased present  
121982/1/04 7 m  Pezzata Rossa diseased present  
147096/05 48 m  Frisona  diseased present  
6323/05 22 m  cross-breed diseased present  
106425/06 3 m  Piemontese  diseased present  
34986/09 49 m  cross-breed diseased present  
35120/09 12 m cross-breed diseased present  
78122/10 44 m cross-breed diseased present  
12894/10 24 m Piemontese  diseased present  
42432/10  3,5 m  cross-breed diseased present  
93342/09 36m  Piemontese diseased present  
56472/10 18 m  Piemontese diseased present  
61201/10 32 m  Piemontese diseased present  
124791/09 8 m  cross-breed diseased present  
66095/6/10 3m Piemontese diseased present  
84580/10 84 m  Pezzata Rossa diseased present  
83090/10 48 m  Piemontese diseased present  
49557/1/2/09 foetus cross-breed diseased present  
13145/11 132 m  Piemontese  diseased present  
40973/09 1 m  Frisona  diseased present  
116716/02 132 m  cross-breed diseased present  
66741/09 26 m  Pezzata Rossa diseased present  
36700/09 4 m  cross-breed diseased present  
105805/02  108 m  Piemontese  diseased present  
59587/2/04 120 m  Piemontese  diseased absent  
49164/10 108 m  Piemontese  diseased absent  
20561/10 72,5 m  Frisona diseased absent  
30132/08 84 m cross-breed diseased absent  
25001/10 3,5 m  frisona diseased absent  
139943/07 75 m  Frisona  diseased absent  
126354/07 6 m  Piemontese  diseased absent  
58389/09 15 m  Piemontese diseased absent  
109298/07 23 m  cross-breed diseased absent  
112142/09 10 m  Piemontese  diseased absent  
102290/09 42 m  Pezzata Rossa diseased absent  
79272/09  36 m  Frisona  diseased absent  
5966/08 65 m  Piemontese diseased absent  
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2196/08 68 m  Frisona diseased absent  
131662/07 80 m  Piemontese diseased absent  
54528/07 foetus Piemontese diseased absent  
49560/09 5 gg cross-breed diseased absent  
34593/10 120,5 m cross-breed diseased absent  
72163/04 120 m  cross-breed diseased absent  
90201/04 29 m Piemontese diseased absent  
125883/09 2 m  Piemontese  diseased absent  
64541/09 45 m  Frisona  diseased absent  
45143/2/10 8 m  Frisona  diseased absent  
Table. 2: Animals considered in the study 
 
5.2 Single-labelling immunohistochemistry (IHC) 
 
Following formaldehyde ﬁxation, brain sections (5 mm thick) from each animal were 
coronally cut. Slices of the frontal cortex, hippocampus, cerebellum and brainstem were 
sampled, embedded in paraffin wax, sectioned coronally at a thickness of 5 μm and mounted 
on a glass slide. The tissues were then immunostained to detect Aβ. The slides were dewaxed 
and rehydrated by routine methods and then immersed in 98% formic acid for 10 min. To 
enhance Aβ immunoreactivity, after washing in distilled water, the sections were then boiled 
in citrate buffer (pH 6.1) for 10 min. Endogenous peroxidase activity was blocked in 3% 
hydrogen peroxide for 20 min at room temperature (RT). To block nonspeciﬁc tissue 
antigens, the sections were incubated with 5% normal goat serum for 20 min at RT. The 
primary monoclonal antibodies were incubated with the tissue overnight at 4°C. Two 
antibodies were used as primary antibodies: polyclonal APP (Abnova, Taipei City, Taiwan; 
1:100 dilution) directed against APP, and monoclonal antibody 4G8 (Signet - Covance, 
Emeryville, California; 1:500 dilution) directed to the epitope in residues 17–24 of Aβ. After 
rinsing, a biotinylated secondary antibody (1:200 dilution; Vector Laboratories, Burlingame, 
CA) was applied to the tissue sections for 30 min at RT, followed by the avidin-
biotinperoxidase complex (Vectastain ABC kit; Vector Laboratories, Burlingame, CA), 
according to the manufacturer’s protocol. The immunoreactivity was visualized using 3,3’-
diaminobenzidine (Dakocytomation, Carpinteria, CA) as a chromogen; the sections were then 
counterstained with Meyer’s hematoxylin. For controls, the primary and secondary antibodies 
were omitted. A human brain tissue affected with AD and provided by Institute Carlo Besta 
(Milan, Italy) was used as positive control. 
50 
 
All four neuroanatomical areas (frontal cortex, hippocampus, cerebellum and brainstem) of 
each animal were observed under a light microscopy and evaluations for APP, and 4G8 
immunoreactivity were done. The classification for APP positivity was assessed only by 
presence or absence of the signal while for 4G8 positive-deposits two different morphological 
types were evaluated: those types included intracellular (intraneuronal) and extracellular (glia-
associated) accumulations of Aβ and they was scored quantitatively at all sites examined. The 
scoring system assessed the “amount and/or intensity” of 4G8 positive-deposits on the 
following scale: 0, absent; 1, slight; 2, moderate; 3 marked. 
 
5.3 Lipofuscin staining 
 
Some of the brain areas with the major Aβ deposition belonging to cattle older than 108 
months were selected for a double immunohistochemistry, to highlight lipofuscin deposition. 
Tissue sections were dewaxed, rehydrated, formic acid treated, and boiled as in the IHC 
protocol described above. After unmasking, the sections were washed in distilled water and 
processed according to a dual-immunohistochemistry protocol. Endogenous peroxidase 
activity was blocked in 3% hydrogen peroxide for 20 min at RT. To block nonspecific tissue 
antigens, the sections were incubated with 5% normal goat serum for 20 min at RT. Primary 
monoclonal antibody 4G8 (SIGNET-Covance, Emeryville, California; 1:500 dilution), was 
applied overnight at 4°C. After rinsing, a biotinylated secondary antibody (1:200 dilution; 
Vector Laboratories, Burlingame, CA) was applied to the tissue sections for 30 min at RT, 
followed by the avidin-biotinperoxidase complex (Vectastain ABC peroxidase kit; Vector 
Laboratories, Burlingame, CA), according to the manufacturer’s protocol. Aβ 
immunoreactivity was visualized using Vector VIP ( Peroxidase Substrate kit, Vector 
Laboratories, Burlingame, CA) as a chromogen; the sections were then incubated with 
primary monoclonal anti-Dityrosine antibody (JaICA, Japan; diluted 1:100 in 5% normal goat 
serum), a specific marker for protein oxidation,  for 1h at RT. After rinsing, a biotinylated 
secondary antibody (1:200 dilution; Vector Laboratories, Burlingame, CA) was applied to the 
tissue sections for 30 min at RT, followed by the avidin-biotin phosphatase complex 
(Vectastain ABC-AP kit; Vector Laboratories, Burlingame, CA), according to the 
manufacturer’s protocol. Lipofuscin immunoreactivity was visualized under light microscopy 
using Blue AP (Alkaline phosphatase substrate kit III, Vector Laboratories, Burlingame, CA) 
as a chromogen. 
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5.4 Immunofluorescence (IF) 
 
Brain sections that stained positive for Aβ by immunohistochemistry, were selected for 
immunofluorescence studies. 
Immunoﬂuorescence staining was performed according to the protocol described below. 
 
  ß-amyloid and glia detection. Double labelling to evaluate the relationship between 
astrocytes and microglia cells with Aβ deposits was performed, according to the 
protocol here described: tissue sections were dewaxed, rehydrated, formic acid treated, 
and boiled in citrate buffer (pH 6.1) as in the IHC protocol described above. After 
unmasking, the sections were washed in distilled water and processed according to a 
dual-immunoﬂuorescence protocol. To block nonspeciﬁc tissue antigens, the sections 
were incubated with 5% TBST-diluted normal goat serum for 20 min at RT. Primary 
antibodies 4G8 (Signet - Covance, Emeryville, California; 1:100 dilution) and 
monoclonal Iba-1 (Wako Chemicals, Richmond, VA, USA; 1:100 dilution) to 
visualize microglial cells or polyclonal GFAP (Dako Cytomation, Glostrup, Denmark; 
1:100 dilution) were applied at RT for 1 h. Tissue sections were then incubated at RT 
with a Alexa fluor 555 anti-mouse or Alexa fluor 488 anti-rabbit secondary antibodies 
(Invitrogen, Life technologies, diluted 1:200) respectively, for 15 min. After rinsing in 
distillate water, the sections were mounted with Mounting Medium with DAPI 
(Vectashield, Vector Laboratories, Burlingame, CA) and examined under a Nikon 
Video Confocal fluorescence microscope (ViCO, Nikon Instruments, Florence, Italy). 
Dark-ﬁeld ﬂuorescence digital images were collected with a DS-U1 camera (Nikon 
Instruments, Florence, Italy) using ﬂuorescein isothiocyanate and tetramethyl 
rhodamine isocyanate ﬁlters. The speciﬁcity of the secondary antibodies was tested by 
applying these antisera without the primary antibodies. No Aβ or glia immunolabeling 
signals were seen after omitting the primary antisera. 
 
 X34 Some of the brain areas with the major Aβ deposition were selected for X34 
staining. Fixed brain tissues were first washed three times with PBS 10 mM for two 
minutes each. Sections were then stained with methoxy-X34 diluted 1:250 in 40% 
ethanol in a humid chamber for 10 min at RT and subsequently washed five times 
with distilled water. Therefore, after one passage in 0,2% NaOH in 80% ethanol for 
two minutes, sections were washed ten minutes in distilled water and then  mounted 
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on a slide glass and cover-slipped with glycerol. Fluorescent staining was visualized 
using Nikon Video Confocal fluorescence microscope (ViCO, Nikon Instruments, 
Florence, Italy) and analyzed using NIS Elements imaging software (Nikon 
Instruments, Florence, Italy). 
  
5.5 Western blot (WB) 
 
Twenty seven frozen brains (from which 25 cortex, 8 cerebella and 7 brainstems were 
analysed) were weighed and homogenized in brain tissue lysis buffer containing 0,5% 
deoxycholic acid, 0,5% NP-40 and 10 mM EDTA diluted in Phosphate buffered saline (PBS) 
at a ratio of 1:10 (w/v) for 1 minute. Homogenates were centrifuged at 5000 x g for 3 minutes 
(Optima TLX ultracentrifuge, rotor TLA 110; Beckman Coulter, Fullerton, CA), and 
supernatants were collected. Sample buffer 3X containing 0.36 M Bistris, 0.16 M Bicine,1,5% 
wlv SDS, 15% w/v sucrose, 2.5% vlv 2-mercaptoethanol, 0.004% w/v bromophenol blue, was 
added to samples, after which samples were sonicated and then placed in boiling water for 5 
min and then immediately chilled on ice. Aliquots (10 μL) of each sample and 5 μL of 
markers (β-amyloid proteins 1-38, 1-40 and 1-42) were loaded into urea gels and subjected to 
electrophoresis. The gels were run at room temperature at 12mA/gel for 10 minutes followed 
by 24 mA/gel for 1 h. Proteins were then transferred into polyvinylidine difluoride 
membranes (Immobilion P; Millipore, Billerica, MA) using a Trans-Blot Semi Dry transfer at 
90 mA for 45 minutes. Membranes were washed with Tris Buffered Saline (TBS), unmasked 
with microwave for 3 minutes in TBS and then blocked with 5% Bovine serum albumin 
(BSA) in TBS with 0,1% Tween at 37°C for 1 hour, and then incubated with primary 
antibody (6E10 antibody, diluted 1:500, Covance) at 4°C overnight. After four washes with 
TBS containing 10% Tween 20, membranes were incubated at room temperature for 1 h with 
anti-mouse biotinylated secondary antibody (diluted 1:3000, GE Health care). After four 
washes with TBS, they were incubated at room temperature for 45 minutes with ABC Elite 
Kit, then blots were developed using ECL Plus (Pierce Biotechnology, USA). 
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5.6 Genetic analysis 
 
DNA was isolated from frozen brain tissue of 30 animals. A genomic region of ~1.8 Kb, 
encompassing exon 2 to exon 4 of the bovine apolipoprotein E (APOE), was amplified. The 
selected region included the entire APOE open reading frame (ORF) (Fig. 4). PCR primers 
were designed using the Primer3 application and their sequences were: APOE_Bt_Ex2_F (5’ 
CCAATCGCAAGCCAGAAG3’) and APOE_Bt_Ex4a_R (5’ 
GAGACTCGGGGTGGGAGTA 3’). 
PCR reactions were carried out with the following conditions: 5 μl of buffer 10x, 2 μl of 
genomic DNA, 30 pmol of each primer, 1 μl of dNTPs, 1 U of Taq polymerase (Roche), 10 μl 
of CG solution (Roche) and 2 μl MgCl2 50 mM, in a final volume of 50 μl (Table 3). 
Thermocycling parameters consisted of an initial denaturation step (95 °C, 10 min) followed 
by 40 cycles of denaturation (94 °C, 1 min), annealing (57 °C, 1 min) and extension (72 °C, 2 
min). ApoE sequence was determined by direct DNA sequencing of the PCR products on ABI 
3130 Genetic Analyser (Life Technologies) by Big Dye terminator v. 3.1 cycle-sequencing 
using the amplification primers pairs and two internal  primers, APOE_Bt_Ex3_F (F (5’ 
GAGGAGCCCCTGACTACCC3’) and APOE_Bt_Ex4b_R (5’ 
ACACCCAGGTCATTCAGGAA 3’). The sequence reactions were prepared as follows: 2 μl 
Sequencing Buffer 10x, 2 μl of Big Dye Terminator v3.1, 3,2 pmol of the sequencing primer, 
50-100 ng of template DNA in a final volume of 20 μl. 
All the ApoE sequences were assembled using the program SeqMan II (Lasergene package, 
DNASTAR Inc.) in order to obtain a consensus sequence for each sample. Polymorphic 
nucleotides were annotated and the final consensus sequences were assembled into a single 
data set. Each variable site was enumerated based on the corresponding position in the bovine 
ApoE sequence. Eventually, allele frequencies of the detected polymorphisms were 
calculated.  
 
 
 
 
Fig. 4: Genomic regions of the bovine APOE gene. 
(Light green = mRNA; dark green = ORF; red arrows = PCR primers).   
  
exon 1 exon 2 exon 3 exon 4 
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Table 3: PCR mix. 
 
5.7 Statistical analysis 
  
Statistical analysis on IHC and WB results was performed employing Chi-square test, carried 
out using the SISA online tool 
(http://www.quantitativeskills.com/sisa/statistics/twoby2.htm), which, in case of small 
number of data, suggests to apply Fisher test. When more than two classes were tested for 
association, the Epitools website was used 
(http://epitools.ausvet.com.au/content.php?page=chi_sq). In genetics, the same websites 
were used to look for association between each polymorphism detected and WB and IHC 
profiles. The analysis were performed by categorizing the animals according to the following 
criteria: 
 
1) Positive or negative cases at the WB analysis; 
2) Cases with intracellular or extracellular Aβ accumulation  in the cortex or its absence at 
IHC analysis; 
3) Cases with a strong or weak  intensity of the signal or its absence in the cortex at IHC 
analysis;  
4) Cases with the intracellular or extracellular Aβ accumulation  in the hippocampus or its 
absence at IHC analysis; 
5) Cases with a strong or weak  intensity of the signal or its absence in the hippocampus at 
IHC analysis. 
  
REAGENTS AMOUNT  (μl) 
Buffer 10x  5 
Primer F  1,5 
Primer R  
MgCl2 50 mM 
 1,5 
 2 
dNTPs  1 
Roche Taq polimerase  0,2 
H2O  26,8 
CG solution  10 
DNA  2 
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Chapter 6: Results 
 
6.1 Single-labelling immunohistochemistry (IHC) and statistical 
analysis 
 
In this study the immunoreactivity to 4G8 was detected by IHC analysis in 59 out of the 102 
cattle examined. The 4G8 antibody is directed against a central epitope of the APP protein 
(17-24), and a cross reaction with APP cannot be completely ruled out. However, Aβ 
immunopositive deposits occurred in two different patterns which were detectable after acid 
formic pretreatment: the intracellular and the extracellular pattern. The intracellular pattern is 
characterized by fine and randomly dispersed Aβ-immunoreactive granules in the cytoplasm 
of neurons, located close to the nucleus (Fig. 5-6) while the extracellular pattern is 
characterized by aggregates frequently associated to glia or randomly dispersed in each brain 
area (Fig. 7-8).  
In general 16 out of 59 IHC positive cases presented exclusively Aβ extracellular pattern 
(mean age at death: 84 months); 2 cattle out of 59 IHC positive cases presented exclusively 
Aβ intracellular pattern (mean age at death: 48 months); 41 presented the coexistence of the 
extracellular and intracellular patterns (mean age at death: 128,4 months) and the remaining 
43 animals were completely negative (mean age at death: 17,1 months). Considering the four 
neuroanatomical areas, cattle with exclusively extracellular pattern presented marked Aβ 
deposits (score 3) localized in cerebral cortex (2/16) principally restricted to the gray matter 
and hippocampus (1/16), where fine and randomly dispersed Aβ immunoreactive granules 
were frequently present in almost all neurons of the dentate gyrus. Cattle with exclusively 
intracellular pattern presented slight Aβ deposits principally localized in cerebral cortex (2/2) 
and cattle with the coexistence of intra and extracellular patterns presented marked Aβ 
deposits principally localized in cerebral cortex (17/41), hippocampus (4/41) and cerebellum 
(4/41) with granular deposits localized at the level of Purkinje cells and in the molecular 
layer. Aβ deposition was never observed in brainstems. 
No Aβ immunoreactive plaques and cerebral vessels were found in all samples. 
It was then investigated the relationship between age of animals and the presence or absence 
of Aβ at IHC: out of 59 IHC positive cases, we have found that 33 animals were older than 
108,5 months, whereas 38 animals, out of 43 IHC negative cases, were younger than 36,5 
months (Table 4). Chi square test disclosed the statistical significance of these data (Table 5). 
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The association between the intracellular or extracellular Aβ localization related to the same 
age ranges was also considered: the majority of animals between 36,5-60 months presented a 
prevalent extracellular Aβ localization (58%), although with aging a coexistence of 
intracellular and extracellular colocalization was mainly present (52% animals between 108,5-
180 months) (Table 6). 
We have then tried to correlate 4G8 immunoreactivity to the health status of the animals and 
interestingly it appeared that in diseased animals Aβ accumulation occurred earlier (from 12,5 
months) than in healthy animals (Table 7). Chi square test highlighted the statistical 
significance of the data regarding healthy and diseased animals (Table 8-9). 
All the brain tissue slices tested for Aβ presence at IHC were also processed for APP and the 
results were similar to those described for 4G8 immunostaining: each section positive to 4G8 
immunostaining resulted positive for the presence of APP. Fine granules of APP 
immunopositivity were mainly localized in the cytoplasm and at the level of the membranes 
of neurons (Fig. 9). 
 
 
IHC 
Age 
(months) 
0-12 12,5-36 36,5-60 60,5-84 84,5-108 108,5-180 >180 
+ 2/59 7/59 6/59 7/59 4/59 27/59 6/59 
- 32/43 6/43 1/43 2/43 0/43 2/43 0/43 
Table 4 : 4G8 positive or negative cattle (considering all brain areas) subdivided by age (months). 
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Table 5: Test chi square: 4G8 positive or negative cattle. 
Chi-square statistic 63.5011; Degrees of freedom 6; P-value <0.0001. 
 
 
 
Table 6: Frequencies of intracellular and extracellular amyloid localization. 
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Table 7: 4G8 positive or negative cattle (considering all brain areas) subdivided by age (months) and 
health status. 
 
 
Table 8: Test chi square: healthy animals on 4G8 positive or negative cattle. 
Chi-square statistic 43.7965; Degrees of freedom:  4; P-value < 0.0001. 
  
IHC 
Health status IHC results Age (months) 
  0-12 12,5-36 36,5-60 60,5-84 84,5- 108 108,5-180 >180 
Healthy + 0/31 1/31 0/31 0/31 1/31 25/31 4/31 
- 17/19 1/19 0/19 0/19 0/19 1/19 0/19 
Diseased + 2/28 6/28 6/28 7/28 3/28 4/28 0/28 
- 15/24 5/24 1/24 2/24 0/24 1/24 0/24 
59 
 
 
 
 
Table 9: Test chi square: diseased animals on 4G8 positive or negative cattle. 
Chi-square statistic 20.9978; Degrees of freedom:  5; P-value < 0.0008 
 
 
 
Fig. 5: 4G8 - Intracellular deposits at the level of frontal cortex (20X).  
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Fig.  6: 4G8 – Intracellular deposits at the level of hippocampus (20X).  
 
Fig.  7: 4G8 – Extracellular deposits at the level of frontal cortex (40X). 
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Fig. 8:  Glia-associated Aβ deposits in frontal cortex (100 X). 
 
Fig. 9: APP - magnification of an hippocampal neuron (40X). 
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6.2 Lipofuscin staining 
 
To evaluate intracellular distribution patterns of lipofuscin and 4G8 immunopositive deposits, 
a dual IHC was performed to simultaneously visualize the two stainings in the same brain 
section. Lipofuscin was stained in blue and β-amyloid in red. Results showed that lipofuscin 
is predominantly present in cytoplasmic regions of neurons exhibiting prominent β-amyloid 
immunolabelling; the labeling patterns of the blue-stained lipofuscin showed that most of this 
material is not co-localized with red-stained β-amyloid in the neurons: most lipofuscin and β- 
amyloid occupy distinct cellular compartments in the same neurons. This separate and distinct 
localization is clearly shown in Fig. 10. 
 
Fig. 10: Dual IHC to detect 4G8 immunoreactive deposits (arrowhead) and lipofuscin (arrow) in cortical 
brain tissue. 
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6.3 Immunofluorescence (IF)  
 
 ß-amyloid, astrocytes and microglia detection. Glial fibrillary acidic protein (GFAP) 
immunofluorescence was used for the specific identification of reactive astrocytes. A 
generalized increase in GFAP signalling and in number of astrocytes was observed in 
brains with a major accumulation of Aβ deposits, but a different localization of 
astrocytes and Aβ deposits was often present in these immunopositive sections, in 
particular at the level of cerebral cortex (Fig. 11-12). In brain areas where coexistence of 
astrocytes and Aβ deposits was present, cell bodies of reactive astrocytes can be seen 
located around the Aβ deposits and their fine processes penetrate them (Fig. 13). The 
majority of compact deposits, with the exception of the small punctuate ones, were 
accompanied by such peripheral reactive astrocytes. GFAP-positive cells were found 
also within the white matter in the areas free of amyloid. To understand the exact 
localization of extracellular amyloid deposits, we performed a double 
immunofluorescence using 4G8 and Iba-1, an antibody against activated microglia. A 
strictly relationship between Aβ extracellular deposits and microglia was observed:  
almost all Aβ extracellular deposits were surrounded and penetrated by immunoreactive 
microglia cells and the most intense Iba-1 immunoreactivity was distributed principally 
in the frontal cortex of all the animals tested. (Fig. 14). 
 
 X34. No positive staining was observed on sections treated with X34 staining. 
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Fig. 11: 4G8 (Alexa fluor 555, red) and GFAP (Alexa fluor 488, green) - frontal cortex. Different 
localization of astrocytes and Aβ in cattle brain (20X). 
 
 
 
 
 
 
 
 
 
 
Fig. 12: 4G8 (Alexa fluor 555, red), GFAP (Alexa fluor 488, green) - frontal cortex. Astrocytosis (20X). 
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Fig. 13: 4G8 (Alexa fluor 555, red), GFAP (Alexa fluor 488, green) and Dapi for nuclei – frontal cortex. 
Strictly relationship between astrocytes and Aβ (100X). 
 
Fig. 14: 4G8 (Alexa fluor 555, red) and Iba-1(Alexa fluor 488, green) – frontal cortex. A) 60X ; B1-B2) 3D 
reconstruction of image A); C-D) 60X. Extracellular Aβ aggregates are strictly correlated to activated microglia. 
 
A B1 B2 
C D 
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6.4 Western Blot (WB) and statistical analysis 
 
A total of 27 cattle brains were examined by WB analysis, including the following areas: 25 
cortex, 8 cerebella and 7 brainstems (Fig. 15). Peptides of Aβ (1-38, 1-40, 1-42 and 3-42) was 
detected in 10 animals out of the 27 examined. Specifically peptide 1-38 was found in 4 
cortex out of 10 positive animals;  peptide 1-40 was found in 7 cortex out of 10 positive 
animals; peptide 1-42 was found in 7 cortex out of 10 positive animals and peptide 3-42 was 
found  only in one cortex out of 10 positive animals; 3 cerebella out of 8 examined were 
positive for amyloid peptides: in particular peptide 1-42 was found in 2 cerebella out of 3 
positive cases and peptide 1-40 only in 1 cerebellum out of 3 examined; no Aβ peptides was 
detected by WB analysis in all 7 brainstems examined. 
However, the intensity of the signal in all the cases analized was weaker than the signal 
detected in humans brain with AD. 
Considering the correlation between the age of the animals and their positivity or negativity at 
WB analysis, although the tested animals were only 27, it appeared that the majority of 
negative cases belonged to the age range under 12,5 months (Table 10); chi square test 
performed was not statistically significant (p<0,8931) (Table 11). 
Relating 27 cases tested to WB analysis with the corresponding IHC positivity or negativity, 
it appeared that 17 cases have been confirmed in both analysis: 8 animals were positive and 7 
were negative to WB and IHC (Table 12). 
Fisher test was performed to highlight the statistical significance of the comparison between 
the two analysis: the obtained p-value (p=0,08931), although not properly statistically 
significant, could indicate a possible trend (Table 13). 
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Fig. 15 : Western Blot analysis performed on brain sections of some animals of the study (CTX = cortex)  
 
BLOT 
Age 
(months) 
0-12 12,5-36 36,5-60 60,5-84 84,5-108 108,5-180 >180 
+ 3/10 1/10 1/10 0/10 1/10 4/10 0/10 
- 7/17 1/17 2/17 1/17 1/17 4/17 1/17 
Table 10 : Western Blot positive or negative cattle (considering all tested areas) subdivided by age 
(months) 
 
 
Table 11: Test chi square: Western Blot positive or negative cattle 
Chi-square statistic 2.2712; Degrees of freedom 6; P-value < 0.8931 (not statistically significant) 
A-Beta 
Syntetic peptides 1-42 1-40  
3-42 
 
LBD 
49164 
CTX 
HUMAN 
BRAIN 
 
101670 
CTX 
34593 
CTX 
34593 
BRAINSTEM 
 
101670 
8 M urea version of Bicine/Tris SDS-PAGE 
1-40 
1-42 
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 WB POSITIVE CASES WB NEGATIVE CASES 
IHC POSITIVE CASES 8 8 
IHC NEGATIVE CASES 2 9 
 
Table 12: Testing for correlations between IHC and Western Blot analysis 
 
 
Table 13:  Fisher test: comparison between WB and IHC results  
P-value = 0,08931. 
 
6.5 Genetic and statistical analysis 
 
PCR products of the expected molecular size (approximately 1750 bp) were obtained using 
primers and optimized protocols described in the Methods section. 
Sequence analysis of the ApoE gene of the 30 cattle resulted in the identification of nine 
SNPs. A list of the identified polymorphisms with the indication of their position in the 
sequence and relative allele frequencies is shown in Table 14. 
Three polymorphisms were not reported in the GenBank reference database and they included 
one non-synonymous mutation in exon 2 (841 G/T, codon 8, Val→Leu) and two SNPs in 
intron 2  (873 G/A) and intron 3 (1544 G/T). The other polymorphisms have all been reported 
previously. 
There is not a reported relationship between these mutations and evident phenotypic changes: 
the two located in the exon determine two synonymous mutations (exon 3, 1394 C/G, codon 
32, Thr ⇒ Thr and in exon 4, 2034 T/C, codon 146, Ser  ⇒ Ser) and the function of those 
already reported in introns is not known. Interestingly, SNPs at positions 1643 (intron 3) and 
2034 (exon 4) were in complete linkage disequilibrium (Table 14).  
0
2
4
6
8
10
pos WB neg WB
pos IHC
neg IHC
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Chi-square tests performed to look for association between each found polymorphism and 
Western blot and IHC profiles did not detect any statistically significant associations (Table 
15; A,B,C,D,E). In Table 15A was performed Fisher test as suggested by  SISA online tool. 
However, there was an interesting results for the position 876 when association was tested for 
strong or weak intensity of the signal or its absence in the cortex by IHC analysis (Table 16) . 
This result was obtained excluding the category without available cases (intracellular pattern 
in cortex). The obtained p-value (p<0,08931), although not properly statistically significant, 
could indicate a possible trend: the variant “G” (guanine) would seem in close relationship 
with the extracellular Aβ deposits in cerebral cortex, as almost all the “G” were found in cases 
where the Aβ accumulated mainly extracellular in the cortex (7/8), while only one “G” was 
present in cases with both intra- and extra-cortex localization. Finally, no “G” was detected in 
control cattle. 
 
SNP location 
(Ref.Seq. NC_007316.5) 
APOE region Allele frequency 
841 G/T  
(codon 8, Val→Leu) 
exon 2 
 
0.08 
873 G/A intron 2 0.06 
876 C/G intron 2 0.24 
894 T/C intron 2 0.26 
952 C/G intron 2 0.37 
1394 C/G 
(codon 32, Thr) 
exon 3 0.61 
1544 G/T intron 3 0.09 
1643 A/G intron 3 0.38 
2034 T/C 
(codon 146, Ser) 
exon 4 0.38 
Table 14: Identified polymorphisms with their position in the sequence and relative allele frequencies 
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A. Positive or negative cases at the Western blot analysis 
 
 
pos
a
: positive cases at WB. 
neg
b
: negative cases at WB 
 
B. Cases with intracellular or extracellular Aβ accumulation  in the cortex or its absence at IHC 
analysis 
 
 
 
extra
c:  extracellular Aβ accumulation in the cortex at IHC analysis. 
intra
d:   intracellular Aβ accumulation in the cortex at IHC analysis.  
int-ext
e:  intracellular and extracellular Aβ accumulation in the cortex at IHC analysis. 
negative
f
:  negative cases at IHC analysis. 
  
876 894 952
pos/neg blot C G T C C G
posa 8 4 posa 8 4 posa 6 6
negb 11 5 negb 12 4 negb 9 7
p< 0.31304 p<0.28986 p<0.74726
1394 1544 1643 2034
C G G T A G T C
posa 7 5 posa 11 1 posa 8 4 posa 7 5
negb 8 10 negb 15 1 negb 9 7 negb 9 9
p<0.45524 p<0.50794 p<0.2637 p<0.26479
876 894 952
cortex intra extra C G T C C G
extrac 9 7 extrac 11 5 extrac 9 7
intrad 0 0 intrad 0 0 intrad 0 0
int-exte 5 1 int-exte 5 1 int-exte 4 2
negativef 6 0 negativef 4 2 negativef 2 4
p <0.091 p <0.7635 p<0.4848
1394 1544 1643 2034
C G G T A G T C
extrac 8 8 extrac 15 1 extrac 10 6 extrac 10 6
intrad 2 0 intrad 2 0 intrad 0 2 intrad 0 2
int-exte 2 4 int-exte 5 1 int-exte 4 2 int-exte 4 2
negativef 4 2 negativef 6 0 negativef 2 4 negativef 2 4
p<0.3598 p <0.673 p<0,238 p<0,238
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C. Cases with a strong or weak  intensity of the signal or its absence in the cortex at IHC analysis 
 
 
strong
g
: strong intensity of the signal at IHC analysis. 
weak
h
: strong intensity of the signal at IHC analysis. 
no signal
i
: absence of the signal at IHC analysis. 
 
D. Cases with the intracellular or extracellular Aβ accumulation in the hippocampus or its absence 
 
 
 
ext
j: extracellular Aβ accumulation  in the hippocampus. 
int
k: intracellular Aβ accumulation  in the hippocampus. 
ext-int
l:  extracellular and intracellular Aβ accumulation  in the hippocampus. 
negative
m
:  absence of Aβ accumulation in the hippocampus. 
  
876 894 952
IHC cortex signal C G T C C G
strongg 5 1 strongg 5 1 strongg 5 1
weakh 5 3 weakh 7 1 weakh 5 3
no signali 6 0 no signali 4 2 no signali 2 4
p<0.2151 p<0.6097 p<0,206
1394 1544 1643 2034
C G G T A G T C
strongg 4 4 strongg 7 1 strongg 6 2 strongg 6 2
weakh 3 5 weakh 8 0 weakh 5 3 weakh 5 3
no signali 4 2 no signali 6 0 no signali 2 4 no signali 2 4
p<0,558 p<0.3998 p<0,3998 p <0,3998
876 894 952
Hippocampus C G T C C G
extj 3 3 extj 4 2 extj 3 3
intk 3 1 intk 3 1 intk 3 1
ext- intl 2 0 ext- intl 2 0 ext- intl 2 0
negativem 10 4 negativem 11 3 negativem 7 7
p<0,5763 p<0,8048 p<0,4858
1394 1544 1643 2034
C G G T A G T C
extj 4 2 extj 5 1 extj 3 3 extj 3 3
intk 1 3 intk 4 0 intk 3 1 intk 3 1
ext- intl 2 0 ext- intl 2 0 ext- intl 2 0 ext- intl 2 0
negativem 7 7 negativem 13 1 negativem 8 6 negativem 8 6
p<0,3164 p<0,7562 p<0,5707 p <0,5707
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E. Cases with a strong or weak  intensity of the signal or its absence in the hippocampus at IHC 
analysis 
 
 
strong
n
: strong signal in the hippocampus at IHC analysis. 
weak
o
: weak signal in the hippocampus at IHC analysis. 
no signal
p
: absence of the signal in the hippocampus at IHC analysis. 
 
Table 15 (A, B, C, D, E): Chi-square test.  A= adenine; C= citosine; G= guanine; T= timine. 
 
 
  876  
  C G 
extra 9 7 
intra 0 0 
int-ext 5 1 
negative 6 0 
 
Table 16: Chi-square statistics. 4.6229; Degrees of freedom:  2; P-value < 0.091. 
 
  
876 894 952
Hippocampus signal C G T C C G
strongn 2 0 strongn 2 0 strongn 2 0
weako 5 3 weako 6 2 weako 5 3
no signalp 10 4 no signalp 11 3 no signalp 7 7
p<0,5784 p<0,7358 p<0,3895
1394 1544 1643 2034
C G G T A G T C
strongn 2 2 strongn 4 0 strongn 2 2 strongn 2 2
weako 4 4 weako 7 1 weako 5 3 weako 5 3
no signalp 7 7 no signalp 13 1 no signalp 8 6 no signalp 8 6
p<1 p<0,7409 p<0,9165 p<0.9165
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Chapter 7:  Discussion 
 
Aβ deposition in the brain has been widely investigated to date in many animal species in an 
attempt to discover a suitable animal model to provide insights into the pathology of human 
cerebral Aβ amyloidosis. Even if a large amount of data about Aβ deposition in the brain is 
available for numerous species, both domestic and wild, but mainly belonging to the category 
of carnivores (i.e. dog and cats), little is still known about the features of Aβ deposition 
process in the large herbivores. Aim of the present study was at first to characterize the 
features of Aβ deposition in cattle brain in relation to age and health status, in order to shed 
light on a possible formation process of Aβ in such species, which had never been 
investigated earlier. Second aim of our investigations was to compare the obtained findings 
with the knowledges acquainted to date about the neuropathological and genetic aspects of Aβ 
deposition process in human brains. Eventually, the third aim was to assess if cattle could 
represent a suitable animal model to disclose the mechanisms underlying cerebral Aβ 
accumulation in man.  
Regarding immunohistochemical investigations, out of the 102 cattle brains examined in the 
present study, 59 tested positive for the presence of Aβ whereas 43 resulted negative. About 
56% of the cases which tested positive for Aβ presence were older than 109 months, whereas 
nearly 88% of the cases testing negative for Aβ were younger than 36 months. Another 
interesting emerging finding was that on the 102 samples tested, 37 out of the 39 cases older 
than 85,5 months (95%) were positive for Aβ deposition (Table 4 ). 
Chi square test performed confirmed the statistically significance of this result (p < 0,0001, 
Table 5). The aforementioned data would allow the supposition that Aβ deposition in the 
brain is an age-related process mainly involving cases older than 108 months (9 years). Our 
findings are similar to what described in humans, where it has been reported that the number 
of non-demented individuals presenting with cerebral Aβ deposits in the form of senile 
plaques was higher in older age groups (Hof et al., 1996). In a recent study by Rodrigue et al. 
(2012) on cognitively normal adults who underwent Aβ PET imaging it was demonstrated 
that cerebral Aβ deposition increases with age and is particularly elevated in about 20% of 
adults aged 60 and over. 
Several studies regarding other animal species would support the aforementioned hypothesis. 
In a study on the cat brain (Gunn-Moore et al., 2006), Aβ deposits were 
immunohistochemically detected inside neurons as well as extracellularly, and the staining 
intensity appeared to be age-dependent. 
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Aβ deposition was shown to be closely age-dependent also in the brain of rhesus monkeys 
(Cork et al., 1990) and of dogs (Cummings et al., 1995); in the latter species such a finding 
was particularly evident in the cortex area, similarly to what displayed by the cattle examined 
in the present study.         
By examining the classification of the same data according to the health status of the cases 
considered, it appeared that, in the healthy subjects, β-amyloid deposition was most 
frequently detected in cases older than 108 months (29/31 = 94%), whereas the 89 % (17/19) 
of the cases free of β-amyloid deposition belonged to the age range below 12 months. 
Considering diseased animals, we evidenced that the presence of a neuropathological 
affection induces an early accumulation of β-amyloid in an uniform way among all the age 
ranges considered starting from 13 months. In the category of diseased cases, cattle devoid of 
cerebral β-amyloid accumulations (15/24 = 62%) were mainly younger than 12 months. On 
the basis of the findings obtained it is conceivable that β-amyloid accumulation process 
seemingly increases concurrently with age, as reported in humans (Hof et al., 1996), and, in 
case of concomitant diseases, it could be hypothesized that an underlying neuropathological 
process may speed up cerebral Aβ accumulation. 
By examining the frequencies of Aβ localization (Table 6), it was confirmed that the youngest 
cases were mainly negative; moreover, Aβ deposition started to increase with age, at first 
mainly displaying an extracellular pattern (38% between 12,5-36 months, 58%  between 36.5-
60 months), and then evolving in the older cattle to a prevalent coexistence of intracellular 
and extracellular deposits (52% between 108.5-180 months, 66%  over  180 months).  
These findings could be explained the theory reported by LaFerla et al., where it has been 
proposed that previously secreted Aβ, which forms the extracellular Aβ pool, could be taken 
up by cells and internalized into intracellular pools. So it is likely that the intracellular Aβ is 
derived from extracellular Aβ pools and is taken up into the cells through receptors or 
transporters (LaFerla et al., 2007). 
A prevalent extracellular localization of Aβ deposits has been frequently described also in the 
brain of other animals, particularly cats (Brellou et al., 2005; Head et al., 2005) and dogs 
(Cummings et al., 1996; Aristotelis et al., 2002): the main extracellular deposition pattern  is 
the diffuse (non-β-sheet) plaque, which can bona fide be assimilated to a form of preamyloid 
deposit, similarly to our findings in cattle. Actually the extracellular Aβ deposits observed in 
the cattle brains examined in our study were not in the form of plaques, but appeared more 
similar to preamyloid lesions, which are also frequently detectable in some form of human 
dementias (Rostagno et al., 2008) as well as in non-demented elderly (Delaere et al., 1990). In 
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human AD brain the extracellular localization of Aβ deposits in the form of senile plaques has 
long been reported, but recently the scientific attention has also been direct to better describe 
the features and investigate the role of Aβ intraneuronal accumulation in AD pathogenesis 
(Gouras et al., 2010). A supposition which has been put forward is that intraneuronal Aβ 
accumulation likely decreases with advancing plaque pathology: such a view would suggest 
that intraneuronal Aβ accumulation should be seen as an early event in the pathology of AD. 
In AD patients diffuse plaques characterize the first stages of the disease and may act as the 
precursor of the neuritic plaques arising afterwards. 
In view of such findings, it could therefore be argued that the preamyloid deposits observed in 
the cattle brains examined could represent an even earlier stage of the Aβ deposition process 
than the diffuse plaques described in domestic carnivores and man. 
The fact that no staining of the tissue sections examined was obtained by employing X34, a 
highly fluorescent derivative of Congo red, is very likely to be ascribed to a lack of the β-
sheet secondary protein structure in the Aβ deposits detected, i.e. a  fibrillar organization. 
APP staining results appeared alike to those obtained by staining the brain sections under 
examination with 4G8 antibody, even if, on APP stained tissues, the staining evaluation has 
been less careful because a quantitative scoring of the signal was not performed. The 
similarity of APP and 4G8 staining results is likely due to the fact that 4G8 antibody 
recognizes the same amino acid sequence (17-24 aa) which also APP antibody is directed 
against to, so a crossreaction between APP and 4G8 can not be rouled out. 
A set of the immunohistochemical investigations performed was carried out on the brain 
sections displaying a more prominent intraneuronal Aβ, in order to exclude an aspecific 
staining of lipofuscin by 4G8 antibody. Lipofuscin is a lipopigment which physiologically 
accumulates in certain cell types during aging. Its gradual intracellular accumulation is 
probably the most characteristic cytological change associated with the process of ageing in 
the brain. Cytochemically, it is considered to be an inert end product of lysosomal breakdown. 
It is known that lipofuscin may be aspecifically stained by anti-Aβ antibodies (Bancher et al., 
1989). Our attempt to discriminate by double immunohistochemical labelling between Aβ and 
lipofuscin deposits revealed that most lipofuscin and Aβ occupy distinct cellular 
compartments in neurons, although there may be some detectable co-localization. Our results 
seem to correlate with findings previously reported by D’Andrea et al. (2002), which assessed 
that the bulk of Aβ 42 immunolabelling is present in areas of the cells not occupied by 
lipofuscin pigments in normal, aged-matched control and AD neurons. This is likely evidence 
for the possibility that Aβ42 containing endosomes may not make a major contribution to 
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lipofuscin formation in neurons. However, since lipofuscin progressively accumulates 
throughout the life of neurons, it is conceivable that the bulk of existing lipofuscin may have 
been deposited within these neurons prior to the onset of Aβ42 accumulation.  
The relationship of glial cells to deposits of Aβ protein has long been studied in the brain of 
both humans and animals. 
Regarding microglia, a study reported in literature on AD brains revealed that about 50% of 
diffuse plaque deposits appeared to be associated with reactive microglia, compared to nearly 
100% of senile plaques (Itagaki et al., 1989). The finding that the intensity of the microglial 
reaction increased with the density of the surrounding amyloid deposits has been disclosed 
also by other studies (D’Andrea et al., 2004), leading to the supposition that the main 
association of microglia with dense core plaques is due to the presence of injured or dying 
neurons as plaque constituents. Such neurons would release lysosomal enzymes, cellular 
DNA and other factors capable of inducing the microglial activation. 
In the cattle brains examined in our study almost all the extracellular β-amyloid deposits 
detected, even if they were not well consolidated in the form of plaques but just displaying as 
preamyloid aggregates, appeared surrounded by activated microglial cells. The involvement 
of microglia cells in the process of preamyloid deposition has not been much investigated to 
date; however, keeping in mind such limitations, we have found an association of preamyloid 
deposits with microglial cells in the brain. Conversely, a previous investigation in the AD 
human brain by El Hachimi and Foncin (1994) reported a lack of involvement of microglial 
cells with preamyloid deposits. Our findings would let us suppose that in preamyloid 
aggregates the amyloid substance itself or some other yet unknown co-factors, probably 
unrelated to neurons, might act as potent microglial-activating materials. 
Regarding astrocytes involvement in the Aβ deposition process it is known from literature 
that these cells appear associated with both neuritic and diffuse plaques. Some studies have 
indicated that astrocytes activate subsequently to microglia suggesting a cause and effect 
relationship (Gatan and Overmier, 1999). Microglia activation can activate astrocytes, which 
in turn act to temper and regulate, sometimes even to inactivate, the phagocytic microglial 
activity.  
In the majority of brain areas analyzed in our study, there was not a real colocalization 
between astrocytes and Aβ; however, when present, we have detected the involvement of 
astrocytes in the process of preamyloid deposition. The finding we obtained confirmed what 
previously described by other authors about astrocyte morphology in AD brains (Itagaki et al., 
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1989): cell bodies of reactive astrocytes labelled with GFAP were located around preamyloid 
deposits, with some of them sending fine processes penetrating the aggregates. 
Regarding immunobiochemical analysis for the detection of the different Aβ isoforms in 
cattle brains, a limitation of the present study was that frozen samples were available for a 
fewer cases (n = 27) than all those tested by IHC. In fact, the Chi square test was not 
statistically significant (p < 0,8931, Table 11). 
Although at WB analysis a small amount of data was obtained, it appeared that the largest part 
(7/17 =41%) of the cases testing negative was younger than 12 months of age, whereas no 
overt association can be drawn between age-range and detection of positivity. Regarding the 
neuroanatomical distribution, the immunobiochemical analysis disclosed the presence of Aβ 
peptides mainly at the level of the cerebral cortex, with 76% of the cortices examined testing 
positive (19/25), whereas 37,5 % (3/8) of the examined cerebella displayed Aβ peptides. Aβ 
was never detected immunobiochemically at the brainstem level (0/7), thus confirming the 
related immunohistochemical results. Regarding the types of Aβ peptides detected, the same 
Aβ isoforms characterizing AD brains were disclosed in the cattle brain, i.e. Aβ 1-38, 1-40, 1-
42 and 3-42, but, given the paucity of the samples tested, no correlations can be drawn among 
Aβ types and age ranges. 
WB results were then compared with IHC analysis to disclose possible correlations. 
Fisher test analysis, although the p-value was not completely statistically significant (p = 
0,08931), likely suggests a trend in the comparison of IHC and WB results. Eight out of the 
10 cases positive at WB analysis were also positive at IHC, while 2 out of 10 resulted 
negative. This is most likely due to the fact that WB is much more sensitive than IHC and 
could have unmasked IHC false negative cases. 
Among the cases detected positive at IHC, 8 out of 16 were also positive at WB analysis, 
while the remaining amount resulted WB negative. Further analysis by mass spectrometry 
(SELDI-TOF), that is going to be performed in our study, could clarify if some of the cases 
testing negative at WB but positive at IHC were false positive because of an aspecific staining 
of the ageing pigment lipofuscin. Moreover, the fewer amount of positive cases detected at 
WB analysis in comparison to IHC could be ascribed to the antibody used to 
immunohistochemically detect Aβ, i.e. 4G8, which can cross react also with APP (Aho et al., 
2010). Therefore it can not be excluded that 4G8 antibody immunoprecipitated not only Aβ 
but also the full-length APP, thus producing some false positive cases at IHC.  
Interestingly, in 6 out of the 8 cases positive at both IHC and WB analysis, the presence of 
Aβ-42 isoform was detected at the immunobiochemical analysis. In other animal species such 
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as dogs (Aristotelis et al., 2002), cats (Head et al., 2005) and monkeys (Kimura et al., 2001), 
the diffuse plaques detected were mainly Aβ-42 positive. It would seem that also in cattle 
amyloid deposits are mainly characterized by the presence of the Aβ-42 peptide and an 
extension of the present study by investigating at WB analysis a larger number of the animals 
considered could confirm this hypothesis. 
The genetic analysis was focused on the ApoE gene because it is known that APOE ε4 is a 
major risk factor for AD in humans (Bekris et al., 2010); specifically two SNPs in exon 4 (at 
codons 112 and 158) of the APOE gene that define three polymorphic alleles (ε2, ε3 and ε4) 
are known. The results from our study show that codons 112 and 158 of the bovine gene are 
not polymorphic. However we found 9 SNPs, among which 3 are novel. 
An interesting result was detected for the position 876 for which statistical analysis suggested 
an association between a SNP at this position and cases with a strong or weak intensity of the 
signal or its absence in the cortex at IHC analysis. Actually, the frequence of the allelic 
variant “G” seemed  to be in relationship with the extracellular cortical accumulation of Aβ. 
The position of the polymorphism, located in one of the first introns near the 5’ UTR, could 
lead to the hypothesis that the 876 polymorphism has a regulatory role in gene expression, as 
reported in many studies (Chorev et al., 2012). 
There are some studies in humans focused on the role of ApoE genotype in the Aβ 
intracellular or extracellular depositions  in the brain. In a study analizing 20 patients with AD 
and 10 controls (Christensen et al., 2010),  the analysis revealed a strong association between 
the ApoE4 genotype and the presence of intraneuronal Aβ. 
Given that ApoE  is involved in neuronal cholesterol transport, it could not be excluded that 
perturbed intracellular trafficking might influence the intraneuronal or extraneuronal Aβ 
aggregation, in human as well as in cattle brains. 
Further studies with the involvement of a larger number of animals could shed light on the 
role of this polymorphism. The next aim of our research will be the study of the role of other 
genes involved in the Aβ deposition process in humans, starting from presenilin 1 (PSEN-1) 
and presenilin 2 (PSEN-2). 
  
79 
 
Ringraziamenti 
 
Se questo progetto è stato realizzato “con amore e dedizione” lo devo a molte persone: 
innanzitutto al Dott. Cristiano Corona, la cui instancabile curiosità è stata la forza trainante 
dell’intero lavoro, alla Dott.ssa Elena Vallino Costassa, preziosa collaboratrice 
nell’esecuzione ed interpretazione della gran parte delle indagini svolte, ed ancora al Dott. 
Simone Peletto ed al Dott. Michele Sola il cui contribuito alla ricerca è stato anch’esso di 
notevole importanza.         
Ringrazio inoltre la Dott. ssa Cristina Casalone ed il Prof. Giorgio Poli, per essere stati 
sempre disponibili durante questi tre anni di studio e per avermi fornito, con le loro 
conoscenze, un supporto fondamentale nella realizzazione di questa tesi.  
Vorrei poi ringraziare tutto il personale tecnico dell’Istituto Zooprofilattico che mi ha 
affiancato anche durante questa esperienza con molta professionalità e disponibilità. 
Un grazie particolare va infine ai miei genitori, per tutto il sostegno fornitomi da sempre nel 
mio percorso di studi, ed inoltre al Prof. Chen, per non aver mai smesso di supportarmi e 
spronarmi, soprattutto nei momenti piu’ difficili.   
Infine ringrazio anche Gina, Giaco e quei nonni che purtroppo non ci sono più, ma che sento 
vicini perché mi stanno tutti guardando dall’alto: questa tesi la dedico a Voi.   
80 
 
References 
 
Aho, L., Pikkarainen, M., Hiltunen, M., Leinonen, V., and Alafuzoff I. (2010) 
Immunohistochemical Visualization of Amyloid-β Protein Precursor and Amyloid-β in Extra- 
and Intracellular Compartments in the Human Brain. J Alzheimers Dis.  20(4), 1015-28. 
 
Almeida, C. G., Takahashi, R. H. and Gouras, G. K. (2006) β-amyloid accumulation impairs 
multivesicular body sorting by inhibiting the ubiquitin–proteasome system. J. Neurosci. 26, 
4277-88 . 
 
Aristotelis, C., Dimakopoulos ,R. and Mayer J.(2002) Aspects of Neurodegeneration in the 
Canine Brain. J Nutr 132, 1579S-82S. 
 
Asai, M., Hattori, C., Szabo, B., Sasagawa, N., Maruyama, K., Tanuma, S. and Ishiura, S. 
(2003) Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. 
Biochem Biophys Res Commun. 301, 231- 35. 
 
Atwood, C. S., Obrenovich, M. E., Liu, T., Chan, H., Perry, G., Smith, M. A. and Martins, R. 
N. (2003) Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and 
toxic properties of amyloid- beta. Brain Res Brain Res Rev. 43 (1), 1-16. 
 
Atwood, C. S., Huang, X., Moir, R. D., Bacarra, N. M., Romano, D., Tanzi, R. E. and Bush, 
A. I. (1998) Dramatic aggregation of Alzheimer Aβ by Cu (II) is induced by conditions 
representing physiological acidosis. J. Biol. Chem. 273, 12817–26. 
 
Ballatore, C., Lee, V. M. and Trojanowski, J. Q. (2007) Tau-mediated neurodegeneration in 
Alzheimer’s disease and related disorders. Nature Rev. Neurosci. 8, 663-72. 
 
Bancher, C., Grundke-Iqbal, I., Iqbal, K., Kim, K. S. and Wisniewski, H. M. (1989) 
Immunoreactivity of neuronal lipofuscin with monoclonal antibodies to the amyloid β-
protein. Neurobiol Aging 10, 125-32. 
 
81 
 
Bekris, L. M., Yu, C.- E., Bird, T. D. and Tsuang, D. W. (2010) Genetics of Alzheimer 
Disease. J Geriatr Psychiatry Neurol 23 (4), 213-27. 
 
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C. 
and Wilson, R. S. (2006) Neuropathology of older persons without cognitive impairment from 
two community-based studies. Neurology 66 (12), 1837-44. 
 
Bi, X., Gall, C. M., Zhou, J. and  Lynch, G. (2002). Uptake and pathogenic effects of amyloid 
β peptide 1–42 are enhanced by integrin antagonists and blocked by NMDA receptor 
antagonists. Neuroscience 112, 827-40. 
 
Bierer, L. M., Hof, P. R., Purohit, D. P., Carlin, L., Schmeidler, J., Davis, K. L. and Perl, D. 
P. (1995) Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer’s 
disease. Arch Neurol 52, 81-88. 
 
Billings, L. M., Green, K. N., McGaugh, J. L. and LaFerla, F. M. (2007) Learning decreases 
Aβ*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J. Neurosci. 
27, 751-61. 
 
Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L. and LaFerla, F. M. (2005) 
Intraneuronal Aβ causes the onset of early Alzheimer’s disease-related cognitive deficits in 
transgenic mice. Neuron 45, 675-88.  
 
Borras, D., Ferrer, I. and Pumarola M. (1999) Age-related Changes in the Brain of the Dog. 
Vet Pathol 36, 202-11.  
 
Boyce, J. T., DiBartola, S. P., Chew, D. J. and Gasper, P.W. (1984) Familial renal 
amyloidosis in Abyssinian cats. Vet Pathol 21 (1), 33-8. 
 
Brellou, G., Vlemmas, I., Lekkas, S. and Papaioannou, N. (2005) Immunohistochemical 
investigation of amyloid β-protein (Aβ) in the brain of aged cats. Histol Histopathol 20, 725-
31.   
 
82 
 
Bu, G., Cam, J. and  Zerbinatti, C. (2006) LRP in amyloid-β production and metabolism. Ann. 
N. Y. Acad. Sci. 1086, 35-53. 
 
Bugiani, O., Giaccone, G., Frangione, B., Ghetti, B. and Tagliavini, F. (1989) Azheimer 
patients: preamyloid deposits are more widely distributed than senile plaques throughout the 
central nervous system. Neurosci. Lett. 103, 263-8.  
 
Bugiani, O., Giaccone, G., Verga, L., Pollo, B., Ghetti, B., Frangione, B. and Tagliavini, F. 
(1990) Alzheimer patients and Down patients: abnormal presynaptic terminals are related to 
cerebral preamyloid deposits. Neurosci. Lett. 119 (1), 56-9. 
 
Busciglio, J., Gabuzda, D. H., Matsudaira, P. and  Yankner, B. A.  (1993) Generation of β-
amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl Acad. Sci. 
USA 90, 2092-96. 
   
Buttini, M., Orth, M., Bellosta, S., Akeefe, H., Pitas, R.E., Wyss-Coray, T., Mucke, L. 
and Mahley, R. W. (1999) Expression of human apolipoprotein E3 or E4 in the brains of 
Apoe-/- mice: isoform-specific effects on neurodegeneration. J Neurosci. 19 (12), 4867-80.  
 
Caille, I., Allinquant B., Dupont, E., Bouillot, C., Lange,r A., Muller U. and Prochiantz A. 
(2004) Soluble form of amyloid precursor protein regulates proliferation of progenitors in the 
adult subventricular zone. Development 131, 2173-81. 
 
Capucchio, M. T., Marquez, M., Pregel, P., Foradada, P., Bravo, M., Mattutino, G., Torre, C., 
Schiffer, D., Catalano, D. ,Valenza, F.,  Guarda  F. and Pumarola, M. (2009)  Parenchymal 
and Vascular Lesions in Ageing Equine Brains Histological and Immunohistochemical 
Studies.  J. Comp. Path. 142, 61-73. 
 
Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., Xu, H. W., Stern, 
D., McKhann, G. and Yan, S. D. (2005) Mitochondrial Aβ: a potential focal point for 
neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J. 19, 2040-1. 
 
Castano, E. M. and Frangione, B. (1991) Alzheimer’s disease from the perspective of the 
systemic and localized forms of amyloidosis.  Brain Pathol 1, 263-71. 
83 
 
 
Chavez-Gutierrez, L., Tolia, A., Maes, E., Li, T., Wong, P. C. and de Strooper, B. (2008) Glu 
(332) in the Nicastrin ectodomain is essential for gamma-secretase complex maturation but 
not for its activity. J. Biol. Chem. 283, 20096-105. 
 
Chorev, M. and Carmel, L. (2012) The function of introns. Front Genet 3: 55.  
 
Christensen, D. Z., Schneider-Axmann, T., Lucassen, P. J., Bayer, T. A. and Wirths, O. 
(2010) Accumulation of intraneuronal αβ correlate with ApoE4 genotype. Acta 
Neuropathol. 119(5), 555-66.  
 
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. 
J. and Ashe, K. H. (2005) Natural oligomers of the amyloid-β protein specifically disrupt 
cognitive function. Nature Neurosci. 8, 79-84. 
 
Cole, G. and Neal, J.W. (1990) The brain in aged elephants. J Neuropathol Exp Neurol. 49 
(2), 190-2. 
 
Cork, L. C., Masters, C., Beyreuther, K. and  Price, D. L. (1990) Development of Senile 
Plaques Relationships of  Neuronal Abnormalities and Amyloid Deposits. Am J Pathol. 137 
(6), 1383-92. 
 
Coulson, E. J., Paliga, K., Beyreuther, K. and Masters, C. L. (2000) What the evolution of the 
amyloid protein precursor supergene family tells us about its function. Neurochem. Int. 36, 
175-84. 
 
Crystal, H. A., Dickson, D. W., Sliwinski, M. J., Lipton, R. B., Grober, E., Marks-Nelson, H. 
and Antis, P. (1993) Pathological markers associated with normal aging and dementia in the 
elderly. Ann. Neurol. 34 (4), 566-73. 
 
Crystal, A. S., Morais V. A., Pierson, T. C., Pijak D. S., Carlin, D., Lee, V. M. and Doms, R. 
W. (2003) Membrane topology of gamma-secretase component PEN-2. J. Biol. Chem. 278, 
20117-23. 
 
84 
 
Cummings, B. J., Head, E., Ruehl ,W., Norton, W., Milgram and Cotman, C. W. (1996) The 
Canine as an Animal Model of Human Aging and Dementia. Neurobiol. Aging 17,  259-68. 
 
D’Andrea, M. R., Cole, G. M. and Ard, M. D. (2004) The microglial phagocytic role with 
specific plaque types in the Alzheimer disease brain. Neurobiol. Aging 25, 675-83.   
 
D’Andrea, M. R., Nagele, R. G., Gumula, N. A., Reiser, P. A., Polkovitch, D. A., Hertzog, B. 
M. and Andrade-Gordon, P. (2002) Lipofuscin and Aβ42 exhibit distinct distribution patterns 
in normal and Alzheimer’s disease brains.  Neurosci. Lett. 323, 45-9. 
 
Dahms, S. O., Hoefgen, S., Roeser, D., Schlott, B., Guhrs, K. H. and Than M. E. (2010) 
Structure and biochemical analysis of the heparininduced E1 dimer of the amyloid precursor 
protein. Proc. Natl Acad. Sci. USA 107, 5381-86. 
 
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., 
Manness, L., Lin, C., Yu, J., Zhu, H., Ghiso, J., Frangione, B., Stern, A., Schmidt, A. M., 
Armstrong, D. L., Arnold, B., Liliensiek, B., Nawroth, P., Hofman, F., Kindy, M., Stern, D. 
and Zlokovic, B. (2003) RAGE mediates amyloid-β peptide transport across the blood–brain 
barrier and accumulation in brain. Nature Med. 9, 907-13. 
 
Delaère, P., Duyckaerts, C., Masters, C., Beyreuther, K., Piette, F. and Hauw, J. J. (1990) 
Large amounts of neocortical beta A4 deposits without neuritic plaques nor tangles in a 
psychometrically assessed, non-demented person. Neurosci. Lett. 116(1-2), 87-93. 
 
Delaère P., He, Y., Fayet, G., Duyckaerts, C. and Hauw, J. J. (1993) Beta A4 deposits are 
constant in the brain of the oldest old: an immunohistochemical study of 20 French 
centenarians. Neurobiol. Aging 14, 191-4. 
 
DiBartola, S. P., Tarr, M. J., Webb, D. M. and Giger, U. (1990) Familial renal amyloidosis in 
Chinese Shar Pei dogs. J Am Vet Med Assoc 197 (4), 483-7.  
 
Ehehalt, R., Miche,l B., De Pietri Tonelli, D., Zacchetti, D., Simons, K. And Keller, P. (2002) 
Splice variants of the beta-site APP-cleaving enzyme BACE1 in human brain and pancreas. 
Biochem. Biophys. Res. Commun. 293, 30-7. 
85 
 
 
El Hachimi, K. H. and Foncin, J. F. (1994) Do microglial cells phagocyte the beta/A4-
amyloid senile plaque core of Alzheimer disease? C R Acad Sci III,  317(5), 445-51. 
 
Fagan, R., Swindells, M., Overington , J. and Weir, M. (2001) Nicastrin, a presenilin-
interacting protein, contains an aminopeptidase/transferrin receptor superfamily domain. 
Trends Biochem. Sci. 26, 213-4. 
 
Forloni, G., Tagliavini, F., Bugiani, O. and Salmona, M. (1996) Amyloid in Alzheimer’s 
disease and prion-related encephalopathies: studies with synthetic peptides.  Prog Neurobiol 
49, 287-315. 
 
Fortna, R. R., Crystal, A. S., Morais, V. A., Pijak, D. S., Lee, V. M. and Doms, R. W. (2004) 
Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the 
gamma-secretase complex. J. Biol. Chem. 279, 3685-93. 
 
Francis, R., McGrath, G., Zhang, J., Ruddy, D. A., Sym, M., Apfeld, J., Nicoll, M., Maxwell, 
M., Hai, B., Ellis, M. C., Parks, A. L., Xu, W., Li, J., Gurney, M., Myers, R. L., Himes, C. S., 
Hiebsch, R., Ruble, C., Nye, J. S. and Curtis, D. (2002) aph-1 and pen-2 are required for 
Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein 
accumulation. Dev. Cell 3, 85-97. 
 
Frautschy, S. A., Yang, F., Irrizarry, M., Hyman, B., Saido, T. C., Hsiao, K. and Cole, G. M. 
(1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152 
(1), 303-17.  
  
Friedreich, N. and Kekule, A. (1859) Zur amyloidfrage. Arch Pathol Physiol Klin Med 16, 50-
65. 
  
Furukawa, K., Barger, S., W., Blalock, E. M. and Mattson, M. P. (1996a) Activation of K+ 
channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. 
Nature 379, 74-8. 
 
86 
 
Gakhar  Koppole, N., Hundeshagen, P., Mandl, C., Weyer, S. W., Allinquant, B., Muller, U. 
and Ciccolini, F. (2008) Activity requires soluble amyloid precursor protein to promote 
neurite outgrowth in neural stem cell derived neurons via activation of the MAPK pathway. 
Eur. J. Neurosci. 28, 871-82. 
 
Gatan, E. and Overmier, B. J. (1999) Inflammatory pathogenesis in Alzheimer’s disease: 
biological mechanisms and cognitive sequeli. Neurosci Biobehav Rev 23, 615-33. 
 
Gearing, M., Rebeck, G.W., Hyman, B.T., Tigges J. and Mirra, S. S. (1994) Neuropathology 
and apolipoprotein E profile of aged chimpanzees: Implications for Alzheimer disease. Proc 
Natl Acad Sci U S A 91 (20), 9382-6. 
 
Gertz, M. A. (2004) The classification and typing of amyloid deposits. Am J Clin Pathol 121 
(6), 787-9. 
 
Giaccone, G., Tagliavini, F., Linoli, G., Bouras, C., Frigerio, L., Frangione, B. and Bugiani, 
O. (1989) Down patients: extracellular preamyloid deposits precede neuritic degeneration and 
senile plaques. Neurosci. Lett. 97, 232-8. 
 
Giannakopoulos, P., Hof, P. R., Surini, M.,Michel, J. P. and Bouras, C. (1993) Quantitative 
immunohistochemical analysis of the distribution of neurofibrillary tangles and senile plaques 
in the cerebral cortex of nonagenarians and centenarians. Acta Neuropathol. 85, 602-10. 
 
Glenner G.G. and Wong C.W. (1984) Alzheimer's disease: initial report of the purification 
and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res 
Commun. 120(3), 885-90. 
 
Golde, T. E., Estus, S., Younkin, L. H., Selkoe, D. J. and Younkin, S. G. (1992) Processing of 
the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255, 728–30. 
 
Götz, J., Ittner, L. M. and Kins, S. (2006) Do axonal defects in tau and amyloid precursor 
protein transgenic animals model axonopathy in Alzheimer’s disease? J. Neurochem. 98, 993-
1006.  
 
87 
 
Gouras, G. K., Almeida, C. G. and Takahashi, R. H. (2005) Intraneuronal Abeta accumulation 
and origin of plaques in Alzheimer's disease. Neurobiol Aging 26, 1235-44. 
 
Gouras, G. K., Tampellini, D., Takahashi, R.H. and  Capetillo-Zarate, E. (2010)  
Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta 
Neuropathol. 119(5), 523-41.  
 
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., 
Haroutunian, V., Buxbaum, J. D., Xu, H., Greengard, P. and Relkin, N. R. (2000) 
Intraneuronal Aβ42 accumulation in human brain. Am. J. Pathol. 156, 15-20. 
 
Gowing, E., Roher, A. E., Woods, A. S., Cotter, R. J., Chaney, M., Little, S. P. and Ball, M. J. 
(1994) Chemical characterization of Abeta 17-42 peptide, a component of diffuse amyloid 
deposits of Alzheimer disease. J. Biol. Chem. 269 (15), 10987-90. 
 
Gregori, L., Fuchs, C., Figueiredo-Pereira, M. E., Van Nostrand, W. E. and Goldgaber, D.  
(1995) Amyloid β-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. 
Chem. 270, 19702-8. 
 
Grundke-Iqbal, I., Iqbal, K., George, L., Tung, Y. C., Kim, K. S. and Wisniewski, H. M. 
(1989) Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer 
disease. Proc. Natl Acad. Sci. USA 86, 2853-7. 
 
Gruys, E. (2004) Protein folding pathology in domestic animals. J Zhejiang Univ SCI 5 (10), 
1226-38. 
 
Gunn-Moore, D.A, McVee, J., Bradshaw, J.M., Pearson, G.R., Head E. and Gunn-Moore, F.J. 
(2006) Ageing changes in cat brains demonstrated by beta-amyloid and AT8-immunoreactive 
phosphorylated tau deposits. J Feline Med Surg. 8(4), 234-42. 
 
Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E. and Troncoso, J. C. (2001) 
Intraneuronal Aβ-amyloid precedes development of amyloid plaques in Down syndrome. 
Arch. Pathol. Lab. Med. 125, 489-92. 
 
88 
 
Han, P., Dou, F., Li F., Zhang, X., Zhang, Y. W., Zheng, H., Lipton S. A., Xu, H. and Liao, F. 
F. (2005) Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a 
novel excitoprotective mechanism involving modulation of tau phosphorylation. J. Neurosci. 
25, 11542. 
 
Haroutunian, V., Schnaider-Beeri, M., Schmeidler, J., Wysocki, M., Purohit, D. P., Perl, D. 
P., Libow, L. S., Lesser, G. T., Maroukian, M. and Grossman, H. T. (2008) Role of the 
neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol. 65, 1211-17. 
 
Hartmann, T., Bieger, S. C., Brühl, B., Tienari, P. J., Ida, N., Allsop, D., Roberts, G. W., 
Masters, C. L., Dotti, C. G., Unsicker, K. and Beyreuther, K. (1997) Distinct sites of 
intracellular production for Alzheimer’s disease A β40/42 amyloid peptides. Nature Med. 3, 
1016-10120. 
 
Haass, C. and Selkoe, D. J. (2007) Soluble protein oligomers in neurodegeneration: lessons 
from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol.; 8(2), 101-12. 
 
Head, E., Moffat, K., Das, P., Sarsoza, F., Poon, W.W., Landsberg, G., Cotman, C.W. and 
Murphy, M. P. (2005) β-Amyloid deposition and tau phosphorylation in clinically 
characterized aged cats. Neurobiol Aging. 26(5), 749-63. 
 
Herzog, V., Kirfel, G., Siemes, C. and Schmitz, A. (2004) Biological roles of APP in the 
epidermis. Eur. J. Cell Biol. 83, 613-24. 
 
Hill, A. F., Desbruslais, M., Joiner, S., Sidle, K. C., Gowland, I., Collinge, J., Doey, L. J. and 
Lantos, P. (1997) The same prion strain causes vCJD and BSE. Nature 389, 448-50.   
 
Hof, P. R., Bierer, L. M., Perl, D. P., Delacourte, A., Buée, L., Bouras, C. and Morrison, J. H. 
(1992) Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe 
in an 82-year-old patient with preclinical signs of dementia. Regional and laminar distribution 
of neurofibrillary tangles and senile plaques. Arch Neurol. 49 (9), 946-53. 
 
89 
 
Hof, P. R., Cox, K. and Morrison, J. H. (1990) Quantitative analysis of a vulnerable subset of 
pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal cortex. J. 
Comp. Neurol. 301(1), 44-54. 
 
Hof, P. R., Giannakopoulos, P. and Bouras, C. (1996) The neuropathological changes 
associated with normal brain aging. Histol Histopathol 11: 1075-88. 
 
Huse, J. T., Liu, K., Pijak, D. S., Carlin, D., Lee,V. M. and Doms, R. W. (2002) Beta-
secretase processing in the trans-Golgi network preferentially generates truncated amyloid 
species that accumulate in Alzheimer’s disease brain. J. Biol. Chem. 277, 16278-84. 
 
Hussain, I., Powell, D.J., Howlett, D.R., Chapman, G.A., Gilmour, L., Murdock, P.R., Tew, 
D.G., Meek, T.D., Chapman, C., Schneider, K., Ratcliffe, F.S., Dingwall, C. and  Christie, G. 
(2000) ASP1 (BACE2) cleaves the amyloid precursor protein at the β-secretase site. Mol. 
Cell. Neurosci. 16, 609-19. 
 
Hyman, B.T., Van Hoesen, G.W., Beyreuther, K. and Masters, C. L. (1989) A4 amyloid 
protein immunoreactivity is present in Alzheimer's disease neurofibrillary tangles. Neurosci 
Lett. 101,352-5. 
 
Imran, M. and Mahmood, S. (2011) An overview of animal prion diseases. Virol J 8: 493. 
 
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S. and Selkoe, D. (1989) Relationship of 
microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24, 173-
82. 
 
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. 
A., Horne, P., Heslin, D., French, J., Mount, H. T., Nixon, R. A., Mercken, M., Bergeron, C., 
Fraser, P. E., St George-Hyslop, P. and Westaway, D. (2000) Aβ peptide immunization 
reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408, 
979-82. 
 
90 
 
Jarrett, J. T., Berger, E. P. and Lansbury, P. T. Jr. (1993) The carboxy terminus of the β 
amyloid protein is critical for the seeding of amyloid formation: implications for  the 
pathogenesis of Alzheimer’s disease. Biochemistry 32, 4693-7. 
 
Jorissen, E., Prox, J., Bernreuther, C., Weber, S., Schwanbeck, R., Serneels, L., Snellinx, A., 
Craessaerts, K., Thathiah, A., Tesseur, I., Bartsch, U., Weskamp, G., Blobel, C. P., Glatzel, 
M., De Strooper, B. and Saftig, P. (2010) The disintegrin/metalloproteinase ADAM10 is 
essential for the establishment of the brain cortex. J Neurosci. 30, 4833-44. 
 
Kaether, C., Capell, A., Edbauer, D., Winkler, E., Novak, B., Steiner, H. and Haass, C. (2004) 
The presenilin C-terminus is required for ERretention, nicastrin-binding and gamma-secretase 
activity. EMBO J. 23, 4738-48. 
 
Kamenetz, F., Tomita, T., Hsieh H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia S. and 
Malinow, R. (2003) APP processing and synaptic function. Neuron 37 (6), 925-37. 
 
Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., 
Multhaup, G., Beyreuther, K. and Muller-Hill, B. (1987) The precursor of Alzheimer’s 
disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-6. 
 
Keil, U., Hauptmann, S., Bonert, A., Scherping, I., Eckert, A. and Müller, W. E. (2006) 
Mitochondrial dysfunction induced by disease relevant AβPP and tau protein mutations. J. 
Alzheimers Dis. 9, 139-46. 
 
Kim, S. I., Yi, J. S. and Ko, Y. G. (2006)  Amyloid β oligomerization is induced by brain lipid 
rafts. J. Cell Biochem. 99, 878-89. 
 
Kimura, N., Nakamura, S., Goto, N., Narushima, E., Hara, I., Shichiri, S., Saitou, K., Nose, 
M., Hayashi, T., Kawamura, S. and Yoshikawa, Y. (2001) Senile plaques in an aged lowland 
Western Gorilla. Exp Anim. 50 (1), 77-81. 
 
Kinoshita, A., Fukumoto, H., Shah, T., Whelan, C. M., Irizarry, M. C. and Hyman, B. T. 
(2003) Demonstration by FRET of BACE interaction with the amyloid precursor protein at 
the cell surface and in early endosomes. J. Cell Sci. 116, 3339-46. 
91 
 
Kontush, A., Berndt, C., Weber, W., Akopyan, V., Arlt, S., Schippling, S. and Beisiegel, U. 
(2001) Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free 
Radic. Biol. Med. 30 (1), 119–128. 
 
Koo, E. H., Sisodia, S. S, Archer, D. R., Martin, L. J., Weidemann, A., Beyreuther, K., 
Fischer, P., Masters, C. L. and Price, D. L. (1990) Precursor of amyloid protein in Alzheimer 
disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci USA. 87, 1561-65.  
 
LaFerla, F. M., Green, K. N. and Oddo, S. (2007) Intracellular amyloid β in Alzheimer’s 
disesase. Nature 8, 499-509. 
 
Laird, F.M., Cai, H., Savonenko, A.V., Farah, M.H., He, K., Melnikova, T., Wen, H., Chiang, 
H.C., Xu, G., Koliatsos, V.E., Borchelt, D.R., Price, D.L., Lee, H.K. and Wong, P. C. (2005) 
BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta 
amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 25, 
11693-709. 
 
Lalowski, M., Golabek, A., Lemere, C. A., Selkoe, D. J., Wisniewski, H. M., Beavis, R. C., 
Frangione, B. and Wisniewski, T. (1996). The "nonamyloidogenic" p3 fragment (amyloid 
beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J. Biol. Chem. 
271(52), 33623-31. 
 
Langui, D., Girardot, N., El Hachimi, K. H., Allinquant, B., Blanchard, V., Pradier, L. and 
Duyckaerts, C. (2004) Subcellular topography of neuronal Aβ peptide in APPxPS1 transgenic 
mice. Am. J. Pathol. 165, 1465-77. 
 
Lee, J., Retamal, C., Cuitino, L., Caruano-Yzermans, A., Shin, J. E., van Kerkhof, P., 
Marzolo, M. P. and Bu, G. (2008) Adaptor protein sorting nexin 17 regulates amyloid 
precursor protein trafficking and processing in the early endosomes. J. Biol. Chem. 283, 
11501-8. 
 
Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M. and 
Ashe, K. H. (2006) A specific amyloid-β protein assembly in the brain impairs memory. 
Nature 440, 352-7. 
92 
 
 
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, 
C. E., Jondro, P. D., Schmidt, S. D., Wang, K. et al. (1995) Candidate gene for the 
chromosome 1 familial Alzheimer’s disease locus. Science 269, 973-7. 
 
Liu, B. and Hong, J. S. (2003) Role of microglia in inflammation mediated neurodegenerative 
diseases: mechanisms and strategies for therapeutic intervention, J Pharmacol Exp Ther, 304 
(1), 1-7. 
 
Liu, Y., Zhang, Y., Wang, X., Zhang, H., You, X., Liao, F. F. and Xu, H. (2009) Intracellular 
trafficking of presenilin 1 is regulated by amyloid precursor protein and phospholipase D1. J. 
Biol. Chem. 284, 12145. 
 
Lorenzo, A. and Yankner, B. A. (1994) Beta-amyloid neurotoxicity requires fibril formation 
and is inhibited by congo red. Proc. Natl. Acad. Sci. U S A. 91(25), 12243-7. 
 
Luo, W. J., Wang, H., Li, H., Kim, B. S., Shah, S., Lee, H. J., Thinakaran, G., Kim, T. W., 
Yu, G. and Xu, H. (2003) PEN-2 and APH-1 coordinately regulate proteolytic processing of 
presenilin 1. J. Biol. Chem. 278, 7850-4. 
 
Ma, T., Zhao, Y. B., Kwak, Y. D., Yang, Z., Thompson, R., Luo Z., Xu, H. and Liao, F. F. 
(2009) Statin’s excitoprotection is mediated by sAPP and the subsequent attenuation of 
calpain-induced truncation events, likely via rho-ROCK signaling. J. Neurosci. 29, 11226. 
 
Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J. and Reddy, P. H. (2006) 
Mitochondria are a direct site of Aβ accumulation in Alzheimer’s disease neurons: 
implications for free radical generation and oxidative damage in disease progression. Hum. 
Mol. Genet. 15, 1437-49. 
 
Masliah, E., Mallory, M., Hansen, L., De Teresa, R. and Terry, R. D. (1993) Quantitative 
synaptic alterations in the human neocortex during normal aging. Neurology 43, 192-7. 
 
Mattson, M. P. (1997) Cellular actions of beta-amyloid precursor protein and its soluble and 
fibrillogenic derivatives. Physiol. Rev. 77, 1081-132.. 
93 
 
 
Matsuda, S., Matsuda, Y., Snapp, E. L. and D’Adamio, L. (2009) Maturation of BRI2 
generates a specific inhibitor that reduces APP processing at the plasma membrane and in 
endocytic vesicles. Neurobiol. Aging 32, 1400-8. 
 
McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., Bush, 
A. I. and Masters, C. L. (1999) Soluble pool of Aβ amyloid as a determinant of severity of 
neurodegeneration in Alzheimer’s disease. Ann. Neurol. 46 (6), 860-6. 
 
Merlini, G. and Stone, M. J. (2006) Dangerous small B-cell clones. Blood  108 (8), 2520-30. 
 
Meziane, H., Dodart, J.C., Mathis, C., Little, S., Clemens, J., Paul, S. M. and Ungerer, A. 
(1998) Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in 
normal and amnestic mice. Proc Natl Acad Sci USA. 95, 12683-88. 
 
Mizuguchi, M., Ikeda, K. And  Kim, S. U. (1992) Differential distribution of cellular forms of 
β-amyloid precursor protein in murine glial cell cultures. Brain Res. 584, 219-25. 
 
Mori, C., Spooner, E. T., Wisniewsk, K. E., Wisniewski, T. M, Yamaguch, H., Saido, T. C., 
Tolan, D. R., Selkoe, D. J. and Lemere, C. A. (2002) Intraneuronal Aβ42 accumulation in 
Down syndrome brain. Amyloid 9, 88-102. 
 
Morley, J. E., Farr, S. A., Banks, W. A., Johnson, S. N., Yamada, K. A. and Xu, L. (2008) A 
physiological role for amyloid-beta protein: enhancement of learning and memory. J. 
Alzheimer’s Dis. 19, 441-9. 
 
Morris, J. C., Storandt, M., McKeel, D. W. Jr., Rubin, E. H., Price, J. L., Grant, E. A. and 
Berg, L. (1996) Cerebral amyloid deposition and diffuse plaques in “normal” aging: evidence 
for presymptomatic and very mild Alzheimer's disease. Neurology. 46, 707-19. 
 
Morrison, J. H. and Hof, P. R. (1997) Life and death of neurons in the aging brain.  Science. 
278, 412-9. 
 
94 
 
Murphy, C. L., Eulitz, M., Hrncic, R., Sletten, K., Westermark, P., Williams, T., Macy, S. D., 
Wooliver, C., Wall, J., Weiss, D. T. and Solomon, A. (2001) Chemical typing of amyloid 
protein contained in formalin-fixed paraffin-embedded biopsy specimens.  Am J Clin Pathol 
116 (1), 135-42. 
 
Nagele, R. G., D’Andrea, M. R., Anderson, W. J. and Wang, H. Y. (2002) Intracellular 
accumulation of β-amyloid1–42 in neurons is facilitated by the α7 nicotinic acetylcholine 
receptor in Alzheimer’s disease.  Neuroscience 110, 199-211. 
 
Nagele, R. G., Wegiel, J., Venkataraman, V., Imaki, H., Wang, K.-C. and Wegiel, J. (2004) 
Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. 
Neurobiol Aging 25, 663-74. 
 
Nakamura, S., Nakayama, H., Uetsuka, K., Sasaki, N., Uchida, K. and Goto, N. (1995) Senile 
plaques in an aged two-humped (Bactrian) camel (Camelus bactrianus). Acta 
Neuropathol. 90(4), 415-8. 
 
Ndung'u, M., Härtig, W., Wegner, F., Mwenda, J. M., Low, R. W., Akinyemi, R. O. 
and Kalaria, R. N. (2011) Cerebral aβ (42) deposits and microvascular pathology in ageing 
baboons. Neuropathol Appl Neurobiol., 38(5), 487-99. 
 
Nelson, P. T., Greenberg, S. G. and Saper, C. B. (1994) Neurosci Lett.  170(1), 187-90. 
 
Nikolaev, A., McLaughlin, T., O’Leary, D. D. and Tessier-Lavigne, M. (2009) APP binds 
DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981-9. 
 
Niimura, M., Isoo, N., Takasugi, N., Tsuruoka, M., Ui-Tei, K., Saigo, K., Morohashi, Y., 
Tomita, T. and Iwatsubo, T. (2005) Aph-1 contributes to the stabilization and trafficking of 
the gamma-secretase complex through mechanisms involving intermolecular and 
intramolecular interactions. J. Biol. Chem. 280, 12967-75. 
 
O’Brien, R. J. and Wong, P.C. (2011) Amyloid Precursor Protein Processing and Alzheimer’s 
Disease. Annu Rev Neurosci. 34, 185-204. 
 
95 
 
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H. and LaFerla, F. M. (2004) Aβ 
immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates 
via the proteasome. Neuron 43, 321-32. 
 
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, 
R., Mattson, M. P., Akbari, Y. and LaFerla, F. M. (2003) Triple-transgenic model of 
Alzheimer’s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. 
Neuron 39, 409-21. 
 
Oddo, S., Caccamo, A., Smith, I. F., Green, K. N. and  LaFerla, F. M. (2006b) A dynamic 
relationship between intracellular and extracellular pools of Aβ. Am. J. Pathol. 168, 184-94. 
 
Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L. and LaFerla, F. 
M. (2006a) Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of 
Alzheimer disease. A link between Aβ and tau pathology. J. Biol. Chem. 281, 1599-604. 
 
Ogomori, K., Kitamoto, T., Tateishi, J., Sato, Y., Suetsugu, M. and Abe, M. (1989) β-protein 
amyloid is widely distributed in the central nervous system of patients with alzheimer’s 
disease. Am. J. Pathol. 134, 243-51.  
 
Oh, E. S., Savonenko, A. V., King, J. F., Fangmark Tucker, S. M., Rudow, G. L., Xu, G., 
Borchelt, D. R. and Troncoso, J. C. (2009) Amyloid precursor protein increases cortical 
neuron size in transgenic mice. Neurobiol. Aging 30, 1238-44. 
 
Ohsawa, I., Takamura, C., Morimoto, T., Ishiguro, M. and Kohsaka, S. (1999) Amino-
terminal region of secreted form of amyloid precursor protein stimulates proliferation of 
neural stem cells. Eur. J. Neurosci. 11, 1907-13. 
 
Pericak-Vance, M. A., Bebout, J. L., Gaskell, P. C. Jr, Yamaoka, L. H., Hung, W. Y., Alberts, 
M. J., Walker, A. P., Bartlett, R. J., Haynes, C. A., Welsh, K. A., Earl, N. L., Heyman, A., 
Clark, C. M. and Roses, A. D. (1991) Linkage studies in familial Alzheimer disease: evidence 
for chromosome 19 linkage. Am J Hum Genet. 48(6), 1034-50. 
 
Perl, D. P. (2010) Neuropathology of Alzheimer’s disease. Mt. Sinai J. Med., 77 (1), 32-42.  
96 
 
 
Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G. and Cotman, C. W. (1993) 
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly 
state. J. Neurosci. 13(4), 1676-87. 
 
Plant, L. D., Boyle, J. P., Smith, I. F., Peers, C. and Pearson, H. A. (2003) The production of 
amyloid beta peptide is a critical requirement for the viability of central neurons. J. Neurosci. 
23, 5531-5. 
 
Plant, L. D., Webster, N. J., Boyle, J. P., Ramsden, M., Freir, D. B., Peers, C. and  Pearson H. 
A. (2006) Amyloid beta peptide as a physiological modulator of neuronal ‘A’-typeK+ current. 
Neurobiol. Aging  27, 1673-83. 
 
Prelli, F., Castano, E., Glenner, G. G. and  Frangione, B. (1988) Differences between vascular 
and plaque core amyloid in Alzheimer's disease. J Neurochem. 51, 648-51. 
 
Price, J. L. and Morris, J. C. (1999) Tangles and plaques in nondemented aging and 
"preclinical" Alzheimer's disease. Ann. Neurol. 45 (3), 358-68. 
 
Puzzo, D., Privitera, L., Leznik, E., Fa, M., Staniszewski, A., Palmeri A. and Arancio, O. 
(2008) Picomolar amyloid-beta positively modulates synaptic plasticity and memory in 
hippocampus. J. Neurosci. 28, 14537-45. 
 
Qiu, W. J., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., 
Safavi, A., Hersh, L. B. and Selkoe, D. J. (1998) Insulin-degrading enzyme regulates 
extracellular levels of amyloid β protein by degradation. J Biol Chem 273 (49), 32730-8.  
 
Ring, S., Weyer, S. W., Kilian, S. B., Waldron, E., Pietrzik, C. U., Filippov, M. A., Herms, J., 
Buchholz, C., Eckman, C. B., Korte, M., Wolfer, D. P. and Müller, U. C. (2007) The secreted 
beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, 
behavioral, and electrophysiological abnormalities of APP-deficient mice. J. Neurosci. 27, 
7817-26. 
 
97 
 
Rodrigue, K. M., Kennedy, K. M., Devous, M. D., Rieck, J. R., Hebrank, A. C., Diaz-
Arrastia, R., Mathews, D. and Park, D. C. (2012) β-Amyloid burden in healthy aging: 
regional distribution and cognitive consequences. Neurology 78 (6): 387-95. 
 
Roertgen, K. E., Parisi, J. E., Clark, H. B., Barnes D. L., O'Brien, T. D. and Johnson, K. H. 
(1996) A beta-associated cerebral angiopathy and senile plaques with neurofibrillary tangles 
and cerebral hemorrhage in an aged wolverine (Gulo gulo). Neurobiol Aging. 17 (2), 243-7. 
 
Rossner, S., Lange-Dohna, C., Zeitschel, U. and Perez-Polo, J. R. (2005) Alzheimer’s disease 
β-secretase BACE1 is not a neuron-specific enzyme, J Neurochem, 92 (2), 226-34. 
 
Rostagno, A. and Ghiso, J. (2008) Preamyloid lesions and cerebrovascular deposits in the 
mechanism of dementia: lessons from non-beta-amyloid cerebral amyloidosis. Neurodegener 
Dis. 5(3-4), 173-5. 
 
Sandbrink, R., Masters, C. L. and Beyreuther, K. (1994) Beta A4-amyloid protein precursor 
mRNA isoforms without exon 15 are ubiquitously expressed in rat tissues including brain, but 
not in neurons. J. Biol. Chem. 269, 1510-7. 
 
Sasaki, N., Toki, S., Chowei, H., Saito, T., Nakano, N., Hayashi, Y., Takeuchi, M. and 
Makita, Z. (2001) Immunohistochemical distribution of the receptor for advanced glycation 
end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 888 (2), 256-62. 
 
Savistchenko, J., Arellano – Anaya, E., Andréoletti, O. and Vilette, D. (2011) Mammalian 
prions: tracking the infectious entities. Prion 5 (2), 84-7. 
 
Schellenberg, G. D. and Montine, T. J. (2012) The genetics and neuropathology of 
Alzheimer’s disease. Acta Neuropathol.  124(3), 305-23. 
 
Selkoe, D. J. (2000) Toward a comprehensive theory for Alzheimer's disease. Hypothesis: 
Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-
protein. Ann. N.Y. Acad. Sci. 924, 17-25. 
 
98 
 
Shah, S., Lee, S. F., Tabuchi, K., Hao, Y. H., Yu, C., LaPlant, Q., Ball, H., Dann, 3rd C. E., 
Sudhof, T. and Yu, G. (2005) Nicastrin functions as a gamma-secretase-substrate receptor. 
Cell 122, 435-47. 
 
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S, Caccavello, R., Davis, D., Doan, M., 
Dovey, H. F., Frigon, N., Hong, J., Jacobson-Croak, K., Jewett, N., Keim, P., Knops, J., 
Lieberburg, I., Power, M., Tan, H., Tatsuno, G., Tung, J., Schenk, D., Seubert, P., 
Suomensaari, S. M., Wang, S., Walker, D., Zhao, J., McConlogue, L. and John, V. (1999) 
Purification and cloning of amyloid precursor protein beta-secretase from human brain. 
Nature 402, 537-40. 
 
Sipe, J. D. (1994) Amyloidosis. Crit Rev Clin Lab Sci 31, 325-54. 
 
Small, D. H., Clarris, H. L., Williamson, T. G., Reed, G., Key, B., Mok, S. S., Beyreuther, K., 
Masters, C. L. and Nurcombe, V. (1999) Neuriteoutgrowth regulating functions of the 
amyloid protein precursor of Alzheimer’s disease. J. Alzheimers Dis. 1, 275-85. 
 
Smith, M. A., Nunomura, A., Zhu, X., Takeda, A. and Perry, G. (2000) Metabolic, metallic, 
and mitotic sources of oxidative stress in Alzheimer disease. Antioxid. Redox Signal. 2, 413–
20. 
 
Tagliavini, F., Giaccone, G., Frangione, B. and Bugiani, O. (1988) Preamyloid deposits in the 
cerebral cortex of patients with Alzheimer’s disease and nondemented individuals. Neurosci. 
Lett. 93, 191-6. 
 
Takahashi, R. H., Almeida, C. G., Kearney, P. F., Yu, F., Lin, M. T., Milner, T. A. and 
Gouras, G. K. (2004) Oligomerization of Alzheimer’s beta-amyloid within processes and 
synapses of cultured neurons and brain. J. Neurosci. 24 (14), 3592-9. 
 
Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., 
Xu, H., Greengard, P. and Gouras, G. K. (2002). Intraneuronal Alzheimer Aβ42 accumulates 
in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161, 1869-
79. 
 
99 
 
Takeuchi, Y., Uetsuka, K., Murayama, M., Kikuta, F., Takashima, A., Doi, K. and Nakayama 
H. (2001) Complementary Distributions of Amyloid-β and Neprilysin in the Brains of Dogs 
and Cats. Vet Pathol.,  45(4),455-66. 
 
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A., St George-Hyslop, P., Van Keuren, 
M. L., Patterson, D., Pagan, S., Kurnit, D. M. and Neve, R. L. (1987) Amyloid beta protein 
gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235, 
880-4. 
 
Terry, R.D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A. and 
Katzman, R. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse 
loss is the major correlate of cognitive impairment. Ann Neurol. 30, 572-80. 
 
Thinakaran, G., Borchelt, D. R., Lee, M. K., Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., 
Davenport, F., Nordstedt, C. and Seeger, M. (1996) Endoproteolysis of presenilin 1 and 
accumulation of processed derivatives in vivo. Neuron 17, 181-90. 
 
Thinakaran, G. and Koo, E. H. (2008) Amyloid precursor protein trafficking, processing, and 
function. J. Biol. Chem. 283, 29615-19. 
 
Tomlison, B. E., Blessed, G. and Roth, M. (1968) Observations on the brain of non-demented 
old people. J. Neurol. Sci. 7, 331-56. 
 
Tseng, B. P., Green, K. N., Chan, J., Blurton-Jones, M. and LaFerla, F. (2005) Aβ inhibits the 
proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging 29 (11), 1607-18. 
 
Uchida, K., Yoshino, T., Yamaguchi, R., Tateyama, S., Kimoto, Y., Nakayama, H. and Goto, 
N. (1995) Senile plaques and other senile changes in the brain of an aged American 
black bear. Vet Pathol.  32(4), 412-4. 
 
Ulrich, J. (1985) Alzheimer changes in non-demented patients younger than sixty-five: 
possible early stages of Alzheimer’s disease and senile dementia of Alzheimer type. Ann. 
Neurol. 17, 273-7. 
 
100 
 
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. 
B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., 
Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., 
Rogers, G. and Citron, M. (1999) β-Secretase cleavage of Alzheimer's amyloid precursor 
protein by the transmembrane aspartic protease BACE. Science. 286, 735-41. 
 
Vetrivel, K. S., Zhang, Y. W., Xu, H. and Thinakaran, G. (2006) Pathological and 
physiological functions of presenilins. Mol. Neurodegener. 1, 4. 
 
Virchow, R. (1851) Bau und zusammensetzung der amylacea des menschen. Verh Phys Med 
Ges Wurzburg 2, 51-4. 
 
Walker, L. C, Masters, C., Beyreuther, K. and Price, D. L. (1990) Amyloid in the brains of 
aged squirrel monkeys. Acta Neuropathol.  80(4), 381-7. 
 
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, 
M. J. and Selkoe, D. J. (2002).  Naturally secreted oligomers of amyloid β protein potently 
inhibit hippocampal longterm potentiation in vivo. Nature 416, 535-9. 
 
Walsh, D. M. and Selkoe, D. J. (2004) Deciphering the molecular basis of memory failure in 
Alzheimer’s disease. Neuron 44 (1), 181-93. 
 
Walsh, D. M., Tseng, B. P., Rydel, R. E., Podlisny, M. B. and Selkoe, D. J. (2000) The 
oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain. 
Biochemistry 39, 10831-9. 
 
Wang, Z., Wang, B., Yang, L., Guo, Q., Aithmitti, N., Songyang, Z. and Zheng, H. (2009) 
Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral 
and central synaptogenesis. J. Neurosci. 29, 10788. 
 
Waschuk, S. A., Elton, E. A., Darabie, A. A., Fraser, P. E. and McLaurin, J. A. (2001) 
Cellular membrane composition defines Aβ-lipid interactions. J. Biol. Chem. 276, 33561-8. 
 
 
101 
 
Wegiel, J., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur-Kolecka, B., Imaki, H., Wegiel, J., 
Mehta, P. D., Silverman, W. P., Reisberg, B., Deleon, M., Wisniewski, T., Pirttilla, T., Frey, 
H, Lehtimäki, T., Kivimäki, T., Visser, F. E., Kamphorst, W., Potempska, A., Bolton, D., 
Currie, J. R. and Miller, D. L. (2007) Intraneuronal Aβ immunoreactivity is not a predictor of 
brain amyloidosis-β or neurofibrillary degeneration. Acta Neuropathol. (Berl) 113, 389-402. 
 
Weible, M. W. and Hendry, I. A. (2004) What is the importance of multivesicular bodies in 
retrograde axonal transport in vivo? J. Neurobiol. 58(2), 230-3. 
 
Weidemann, A., Eggert, S., Reinhard, F. B., Vogel, M., Paliga, K., Baier, G., Masters, C. L., 
Beyreuther, K. and Evin, G. (2002) A novel epsilon-cleavage within the transmembrane 
domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch 
processing. Biochemistry 41, 2825-35. 
 
West, M. J., Coleman, P. D., Flood, D. G. and Troncoso, J. C. (1994) Differences in the 
pattern of hippocampal neuronal loss in normal ageing and Alzheimer’s disease. Lancet 344, 
769-72. 
 
WHO-IUIS, Nomenclature Sub-Committee (1993) Nomenclature of amyloid and 
amyloidosis. Bulletin of the World Health Organization 71 (1), 105-12. 
 
Wild-Bode, C., Yamazaki, T., Capell, A., Leimer, U., Steiner, H., Ihara, Y. and Haass, C. 
(1997) Intracellular generation and accumulation of amyloid beta-peptide terminating at 
amino acid 42. J. Biol. Chem. 272, 16085-8. 
 
Wirths, O., Multhaup, G., Czech, C., Blanchard, V., Moussaoui, S., Tremp, G., Pradier, L., 
Beyreuther, K. and Bayer, T. A. (2001) Intraneuronal Aβ accumulation precedes plaque 
formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. 
Lett. 306, 116-20. 
 
Wisniewski, H. M., Bancher, C., Barcikowska, M., Wen, G. Y. and Currie, J. (1989) 
Spectrum of morphological appearance of amyloid deposits in Alzheimer’s disease. Acta 
Neuropathol. 78(4), 337-47. 
 
102 
 
Wisniewski, H. M., Narang, H. K. and Terry, R. D. (1976) Neurofibrillary tangles of paired 
helical filaments. J Neurol Sci. 27, 173-81. 
 
Wisniewski, H. M., Vorbrodt, A. W., Moretz, R. C., Lossinsky, A. S. and Grundke-Iqbal, I. 
(1982) Pathogenesis of neuritic (senile) and amyloid plaque formation. Exp Brain Res S5, 3-9. 
 
Wisniewski, K., Jervis, G. A., Moretz, R. C. and Wisniewski, H. M. (1979) Alzheimer 
neurofibrillary tangles in diseases other than senile and presenile dementia. Ann. Neurol. 5, 
288-94. 
 
Woldemeskel, M. (2012) A coincise review of amyloidosis in animals. Vet Med Int 2012: 
427296. 
 
Yamaguchi, H., Hirai, S., Morimatsu, M., Shoji, M. and Nakazato, Y. (1989) Diffuse type of 
senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein 
immunostain. Acta Neuropathol. 77, 314-9. 
 
Yamaguchi, H., Nakazato, Y., Shoji, M., Okamoto, K., Ihara, Y., Morimatsu, M. and Hirai, S. 
(1991) Secondary deposition of beta amyloid within extracellular neurofibrillary tangles in 
Alzheimer-type dementia. Am J Pathol. 138(3), 699-705. 
 
Yazawa, H. Yu, Z. X., Takeda, Le Y., Gong, W., Ferrans, V. J., Oppenheim, J. J., Li, C. C. 
and Wang, J. M. (2001) β amyloid peptide (Aβ42) is internalized via the G-protein-coupled 
receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J. 15, 2454-62 . 
 
Zhang, Y. W. and Xu, H. (2010) Substrate check of gamma-secretase. Nat. Struct. Mol. Biol. 
17, 140-1.  
 
Zhao, G., Mao, G., Tan, J., Dong, Y., Cui, M. Z., Kim, S. H. and Xu, X. (2004) Identification 
of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of 
amyloid precursor protein. J. Biol. Chem. 279, 50647-50. 
 
Zheng, H. and Koo, E. H. (2011) Biology and pathophysiology of the amyloid precursor 
protein. Mol. Neurodegener. 6, 27. 
103 
 
 
Zou, K., Kim, D., Kakio, A., Byun, K., Gong, J. S., Kim, J., Kim, M., Sawamura, N., 
Nishimoto, S., Matsuzaki, K., Lee, B., Yanagisawa, K. and Michikawa, M. (2003) Amyloid 
beta-protein (Abeta)1- 40 protects neurons from damage induced by Abeta1-42 in culture and 
in rat brain. J. Neurochem. 87, 609-19. 
